Withdrawal/Redaction Sheet
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Jeffrey Levi, To: Jill Pizzuto, Re: Today, 6:00 PM (1 page)	06/18/1996	Personal Misfile
002. email	From: Jeffrey Levi, To: Dorothy Karayannis, Re: I am told this is not a surprise (1 page)	06/18/1996	Personal Misfile
003. email	From: DOBER@HRSA.SSW.DHHS.GOV, To: Multiple Recipients, Re: Interviews for Dir, Bureau of Hlth Res Div [partial] (1 page)	06/19/1996	b(6)
004. email	From: Jeremy Benami, To: Many Recipients, Re: FYI - Silverman Bday (4 pages)	06/20/1996	Personal Misfile
005. email	From: DOBER@HRSA.SSW.DHHS.GOV, To: Multiple Recipients, Re: Reference Check Assignments [partial] (1 page)	06/21/1996	b(6)

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUN-1996 16:43:17.47

SUBJECT: RE: CHR / tomorrow-Conference Call w/ Cong. Woolsey

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUN-1996 17:11:12.90

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 09:39:30.35

CC: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 17:03:06.93

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:24-JUN-1996 17:09:04.93

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUN-1996 17:45:01.88

TEXT:
I can be there...jeff...do you need me to provide some background
for Carol?

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:18-JUN-1996 12:14:00.00

SUBJECT: New Conference Listings 06/18/96

TO: levi_j (levi_j@A1@CD) (WHO)
READ:18-JUN-1996 15:57:00.99

TEXT:

CDC National AIDS Clearinghouse
Conference Calendar Database

NEW CONFERENCE LISTINGS
June 18, 1996

The Clearinghouse's Conference Calendar Database contains information about upcoming conferences related to HIV and AIDS.

NAC ONLINE users can search this database by selecting "Clearinghouse Databases" from the NAC ONLINE main menu. When asked to enter a database name, specify "CONF" to search the Calendar.

To access the NAC ONLINE BBS, set your communications software to dial (800) 851-7245, and set the options for 8 data bits, N parity, 1 stop bit, full duplex, and complete a new user questionnaire. Only non-profit organizations, government agencies, educational institutions, and health departments are given full access to NAC ONLINE and the NAC databases.

Overnight, 6 new listings were loaded to the Conference Calendar Database. Their records follow:

TITLE: Strategies for a Changing Health Care Environment: The National Nurse Practitioner Conference 1996
DATE: October 23-26, 1996
LOCATION: Arlington, VA
SPONSOR(S): Nurse Practitioner World News; Nurse Practitioner Business Institute
CONTACT: Nurse Practitioner Education Associates, Ltd., 9556 Wandering Way, Columbia, MD 21045-3244
EVENT TYPE: Conference
TOPICS: Nurse education. Nurse roles. Sexuality. Information sources. Children with HIV/AIDS. Sexual abuse or assault. Case management. Sexually transmitted diseases (STDs). Women. Legislation or regulation. Tuberculosis (TB). Hepatitis. Contraception.
NOTES: Fee: Before August 5, 1996, $300; After August 5, $350; After October 4, $375; student, $250 (enclose copy of ID). Single day

registrations available. Continuing education credits available. Accommodations, (800) 228-9290. Travel, (800) 334-8644 or (800) 521-4041.

TITLE: Winning Grants; Proposal Writing Step by Step
DATE: June 26, 1996
LOCATION: San Diego, CA
SPONSOR(S): Community AIDS Response to Increase Grants (CARING)
CONTACT: Community AIDS Response to Increase Grants (CARING), P.O. Box 85524 (P502E), San Diego, CA 92186-5524, (619) 291-2853, FAX: (619) 692-8668
EVENT TYPE: Workshop
TOPICS: Fundraising. Funding sources. Community organizations.
NOTES: Fee: $50. Pre-registration required. Materials (230 page manual) fee: $45.

TITLE: Co-Conspirators: Impact of Opportunistic Infections with HIV Disease
DATE: July 10, 1996
LOCATION: Vancouver, CA - Canada
SPONSOR(S): University of Alabama School of Medicine, Division of Continuing Medical Education
CONTACT: (800) 433-4584, (800) 521-1177, within New York, FAX: (212) 679-7883, Internet email: whcme@whci.41mad.com
EVENT TYPE: Conference
TOPICS: Opportunistic infections. Pneumocystis carinii pneumonia (PCP). Herpes virus group. Treatment. Therapeutic drugs.

TITLE: Nurses Cancer Symposium; 16th Annual
DATE: October 10-12, 1996
LOCATION: San Diego, CA
SPONSOR(S): ScrippsHealth; Stevens Cancer Center; Scripps Memorial Hospitals
CONTACT: Stevens Cancer Center, P.O. Box 28, La Jolla, CA 92038- 0028, (619) 626-6794, FAX: (619) 626-6793
EVENT TYPE: Symposium
TOPICS: Nurse education. Cancer. Treatment. Case management. Nutrition. Cultural factors. Legislation or regulation.
NOTES: Fee: Before August 15, 1996, $325; After August 15, $350; Students, $125. One day registrations available. Accommodations, (619) 692-2265. Travel, (800) 247-6470.

TITLE: New York States Parents and Teachers Association 1996 Convention
DATE: November 15-17, 1996
LOCATION: Kiamesha Lake, NY
SPONSOR(S): New York State Congress of Parents and Teachers, Inc.
CONTACT: New York State Congress of Parents and Teachers, Inc., 119 Washington Ave., Albany, NY 12210-2284, (518) 462-5326, FAX: (518) 462-5339
EVENT TYPE: Conference
TOPICS: Schools. Adolescents. Children.

NOTES: Exhibition spaces available.

TITLE: Beyond Borders: Caring for the HIV Infected Child
DATE: July 12, 1996
LOCATION: Vancouver, CA - Canada
SPONSOR(S): National Pediatric & Family HIV Resource Center; The Francois Xavier Bagnoud International Pediatric HIV Training Program
CONTACT: Estella Ortega, (201) 268-8251, or (800) 362-0071, FAX: (201) 485-2752, Internet email: nphrc@daiid.umdnj.edu
EVENT TYPE: Symposium
TOPICS: Children with HIV/AIDS. Case management. Developing nations. Nutrition. Cultural factors. Families. Health professional education. Advocacy. Psychological factors. Research programs. Research needs. Immunization.
NOTES: No fee, but pre-registration is preferred.

Information about additional conferences is welcome. Please send E-Mail to Flynn McLean (through NAC ONLINE, or fmclean@cdcnac.aspensys.com via the Internet) at the CDC National AIDS Clearinghouse; include the title, dates, site, sponsoring agency, contact information, registration fee, and topics to be discussed at the conference.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:18-JUN-1996 12:17:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I61Y1RGY4G007VXY@PMDF.EOP.GOV> for levi_j@a1.eop.gov; Tue, 18 Jun 1996 12:14:45 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I61Y5XL4OE00007X@STORM.EOP.GOV> for levi_j@a1.eop.gov; Tue, 18 Jun 1996 12:18:09 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA09511; Tue, 18 Jun 1996 12:17:16 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:18-JUN-1996 11:12:00.00

SUBJECT: CDC AIDS Daily Summary 06/18/96

TO: levi_j (levi_j@A1@CD) (WHO)
READ:18-JUN-1996 15:55:43.20

TEXT:

AIDS Daily Summary
June 18, 1996

****

****

"CDC's Deceitful HIV Scare Campaign"
Wall Street Journal (06/18/96) P. A23; Wright, Michael

In a letter to the editor of the Wall Street Journal, Michael Wright, of Scientific Social Research, criticizes previous letters written by Centers for Disease Control and Prevention officials and former Surgeon General C. Everett Koop. Wright claims that the letter from the CDC, written in defense of the agency's HIV education campaign, falsely claimed that in 1987 the agency did not know that certain groups were at higher risk for HIV than others. Calling those statements "indefensible," he cites a 1987 CDC report and other studies that specifically named high-risk groups and said that people not belonging to any of the

groups had a lower risk of contracting HIV. Wright concludes that CDC officials should have recognized this disparity in risk and should be held responsible for the dishonest scare campaign they engineered.

"In Quests Outside Mainstream, Medical Projects Rewrite Rules"
New York Times (06/17/96) P. A1; Kolata, Gina

The Office of Alternative Medicine, part of the National Institutes of Health, was founded in 1991 by Congress to determine the possible benefits of a variety of treatments not accepted by the conventional medical establishment. The office has not yet proven any alternative therapy to work or fail. Its budget is relatively small--$7,486,000 for fiscal year 1996--and some scientists have criticized the office for distributing money to researchers who have little experience with clinical research or clinical trials. A $920,000 grant was awarded to Leanna J. Standish, a neuropath at Bastyr University in Seattle, for a 1,500- to 2,000-person clinical trial evaluating alternative AIDS therapies. Standish hopes to determine which alternative treatments for HIV have the most potential. Richard Peto, a clinical trial expert, said the study would prove useless because, even as an exploratory program, it lacked a control group.

"Lifeline: Fur's Flying"
USA Today (06/18/96) P. 1D; Vigoda, Arlene

Jeff Getty, the AIDS patient and activist that received a baboon bone marrow transplant last year, is joining other AIDS patients in Washington, D.C., this week for a counter-protest against animal rights activists. Getty has criticized People for the Ethical Treatment of Animals and other groups for delaying AIDS research.

"Why Do We Insist on Scaring Our Children?"
USA Today (06/18/96) P. 13A; Medved, Michael

In a commentary on society's warnings to young people, film critic Michael Medved writes in USA Today that the negativism presented by the schools, the media, and parents concerning issues including AIDS, drugs, divorce, and crime is too strong and is undermining children's hope. He says that the trend toward warning children at younger and younger ages is new and is failing. Moreover, the critic points out that despite increased sex education programs, some schools report increases in unprotected sexual activity. Medved advocates optimism for children and says that scare tactics bring about increased self-pity and feelings of victimization.

"Health Notes: New Convenience in AIDS Drug"
United Press International (06/18/96); Milius, Susan

The antibiotic Zithromax can now be taken by HIV-infected individuals once a week rather than every day. The Food and Drug Administration has approved the new dose formulation of the drug that can help prevent Mycobacterium avium complex (MAC) infections in the blood. MAC, which the CDC estimates affects an

estimated 25 percent of AIDS patients, causes fever, fatigue, diarrhea, and wasting.

"Ribozyme Pharmaceuticals Gets Preliminary Approval for AIDS Drug Trials"
Knight-Ridder (06/18/96); Locke, Tom

Ribozyme Pharmaceuticals has received approval from an advisory panel at the National Institutes of Health to move forward with plans for a clinical trial for an unnamed AIDS drug. The clinical trial will test a new treatment in which cells would be taken from a patient with HIV, treated with the drug, and then returned to the patient. The first phase of the trial may begin within a few months.

"More Than 100 Million Worldwide Predicted To Be HIV-Positive by Year 2000"
Reuters (06/17/96)

A researcher at the University of Maryland Institute of Human Virology in Baltimore estimates that 20 million people worldwide are currently infected with HIV and that 100 million people will have the virus by the year 2000. William Blattner reports that the pattern of HIV infection has shifted quickly and that more than 90 percent of those infected with HIV in the year 2000 will be in developing countries. In the June 1 issue of Internal Medicine News, he projects that the pandemic will become more prevalent in Asia than in Africa over the coming years.

"Agency Formed to Coordinate AIDS Vaccine Development"
Reuters (06/17/96)

The International AIDS Vaccine Initiative, sponsored by the Rockefeller Foundation, was founded to work with non-profit, profit, and government groups to make AIDS vaccine research less risky for private-sector investors. The agency was described in the June 15 issue of the Lancet. Peggy Johnston, scientific director of the project, said the initiative will support research and development aimed at filling in gaps of current programs. She noted that it is especially important to consider the high prevalence of HIV infection in developing countries and to develop vaccines that target different HIV strains.

"Infection and AIDS in Adult Macaques After Nontraumatic Oral Exposure to Cell-Free SIV"
Science (06/07/96) Vol. 272, No. 5267; P. 1486; Baba, Timothy W.; Trichel, Anita M.; An, Li; et al.

Reported cases of HIV-1 transmission by oral-genital exposure have been rare, and a quantitative assessment of the relative HIV risk of oral infection has not been possible. Infection of rhesus monkeys with SIV is the best system to model human HIV-1 transmission, viremia, and disease. Ruth M. Ruprecht, of the Dana-Farber Cancer Institute, and others exposed two rhesus monkeys to SIV orally, and both became infected. The researchers found that the minimum amount of virus required for infection from oral exposure was 6,000 times lower than that needed for rectal infection. They therefore suggest that

infection from intrarectal exposure in humans is more common than infection from oral-genital exposure because rectal infection is facilitated by mucosal tears during sexual intercourse. According to the researchers, the findings do not imply that HIV-1 transmission is likely to occur through casual contact or that the risk for oral infection is limited to high viral levels, as found in blood or semen. The portal of virus entry after oral exposure should be studied further, the researchers suggest, noting that unprotected oral sex should be considered a risk behavior for HIV-1 transmission.

"Japanese Minister Takes Pay Cut to Atone for HIV Contamination"
Nature (06/06/96) Vol. 380, No. 6582; P. 460

Japan's Health and Welfare Minister Naoto Kan has announced that he and vice-minister Hiroshi Tada will take a 20 percent reduction in pay over the next two months in an attempt to atone for the government's role in the tainted blood scandal in the early- to mid-1980s. Kan only became minister in January, so he bears no responsibility for the disaster, which resulted in 2,000 Japanese hemophiliacs becoming infected with HIV from non-heat-treated blood products. He led efforts to expose the ministry's role in the scandal, but, according to Japanese tradition, Kan should take symbolic responsibility. Representatives of hemophiliacs were not satisfied with the action, saying the pay cut is not adequate atonement for the infection of so many people.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:18-JUN-1996 11:15:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
 by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01161VUJPOM8018VH0@PMDF.EOP.GOV> for
 levi_j@a1.eop.gov; Tue, 18 Jun 1996 11:12:27 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
 by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01161VYRIEY600007X@STORM.EOP.GOV> for
 levi_j@a1.eop.gov; Tue, 18 Jun 1996 11:15:51 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA02609; Tue,
 18 Jun 1996 11:15:00 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: OASIS Manager (OASISMGR) (OA)

CREATION DATE/TIME:18-JUN-1996 12:53:21.26

SUBJECT: West Wing Tours

TO: T J Glauthier (GLAUTHIER_T) (OMB)
READ:19-JUN-1996 22:02:56.35

TO: Mary Ellen Glynn (GLYNN_M) (WHO)
READ:18-JUN-1996 15:36:01.94

TO: Jason S. Goldberg (GOLDBERG_JS) (OPD)
READ:18-JUN-1996 12:52:46.90

TO: Terry W. Good (GOOD_T) (WHO)
READ:19-JUN-1996 09:08:42.16

TO: David S. Goodin (GOODIN_D) (WHO)
READ:NOT READ

TO: Laura A. Graham (GRAHAM_L) (WHO)
READ:18-JUN-1996 13:52:35.19

TO: Theresa F. Granger (GRANGER_T) (WHO)
READ:18-JUN-1996 13:45:14.77

TO: Francho J. Gray (GRAY_F) (OA)
READ:24-JUN-1996 17:22:30.06

TO: Wendy E. Gray (GRAY_W) (NSC)
READ:18-JUN-1996 13:52:51.14

TO: Julia R. Green (GREEN_J) (WHO)
READ:NOT READ

TO: Sara Grote (GROTE_S) (WHO)
READ:NOT READ

TO: Christopher M. Gruin (GRUIN_C) (WHO)
READ:18-JUN-1996 13:41:33.26

TO: Daniel J. Gunia (GUNIA_D) (OA)
READ:18-JUN-1996 13:04:11.23

TO: LAWRENCE J. HAAS (HAAS_L) (OMB)
READ:18-JUN-1996 12:56:26.52

TO: Mary A. Haines (HAINES_M) (NSC)
READ:26-JUN-1996 11:01:23.26

TO: Marcia L. Hale (HALE_M) Autoforward to: R. Lawton Jordan III (JORDAN_RL) (WHO)
READ:19-JUN-1996 17:42:32.95

TO: Sheryl L. Hall (HALL_S) (OA)
READ:18-JUN-1996 15:06:17.76

TO: William A. Halter (HALTER_W) (OMB)
READ:18-JUN-1996 13:08:43.18

TO: Karen L. Hancox (HANCOX_K) (WHO)
READ:18-JUN-1996 12:54:45.69

TO: Kirk Hanlin (HANLIN_K) (WHO)
READ:28-JUN-1996 16:15:00.38

TO: Bruce D. Harding (HARDIN_B) Autoforward to: Remote Addressee (Bruce D. Harding@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Michael E. Harman (HARMAN_M) (OA)
READ:18-JUN-1996 14:47:48.65

TO: Skila S. Harris (HARRIS_S) Autoforward to: Remote Addressee (Skila S. Harris@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: John P. Hart (HART_J) (WHO)
READ:18-JUN-1996 13:06:35.72

TO: Wendy Hartman (HARTMA_W) Autoforward to: Remote Addressee (Wendy Hartman@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Cookab Hashemi (HASHEMI_C) (WHO)
READ:18-JUN-1996 12:54:28.02

TO: David J. Hawes (HAWES_D) (NSC)
READ:NOT READ

TO: Ardenia R. Hawkins (HAWKINS_AR) (NSC)
READ:NOT READ

TO: James A. Hawkins (HAWKINS_J) (WHO)
READ:18-JUN-1996 12:54:41.79

TO: Anne Hawley (HAWLEY_A) (WHO)
READ:18-JUN-1996 13:01:45.12

TO: Susan Hazard (HAZARD_S) (WHO)
READ:18-JUN-1996 13:29:58.07

TO: Paul R. Hegarty (HEGART_P) Autoforward to: Remote Addressee (Paul Hegarty@LNGATE@EOPMRX) (VPO)

READ:NOT READ

TO: James T. Heimbach (HEIMBACH_J) (WHO)
READ:18-JUN-1996 13:02:58.65

TO: Wendy A. Heistad (HEISTAD_W) (WHO)
READ:19-JUN-1996 18:32:32.37

TO: Kenneth K. Hembree (HEMBREE_K) (OA)
READ:18-JUN-1996 14:32:11.17

TO: Eunice C. Hendrix (HENDRIX_E) (WHO)
READ:18-JUN-1996 12:59:47.03

TO: Kathleen M. Hennessy (HENNESSY_K) (WHO)
READ:18-JUN-1996 17:01:48.35

TO: Madge H. Henning (HENNING_M) (WHO)
READ:18-JUN-1996 13:33:46.52

TO: Alexis Herman (HERMAN_A) (WHO)
READ:NOT READ

TO: Nancy V. Hernreich (HERNREICH_N) (WHO)
READ:19-JUN-1996 10:14:10.05

TO: Kathryn Higgins (HIGGINS_K) Autoforward to: Elizabeth M. Toohey (TOOHEY_E) (WHO)
READ:NOT READ

TO: David WHCATRIP Hill (HILL_D) (WHO)
READ:NOT READ

TO: Brenda I. Hilliard (HILLIARD_B) (NSC)
READ:18-JUN-1996 12:53:38.80

TO: Joanne M. Hilty (HILTY_J) Autoforward to: Remote Addressee (Joanne M. Hilty@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Marc A. Hoberman (HOBERMAN_M) (WHO)
READ:18-JUN-1996 14:46:01.60

TO: Elgie Holstein (HOLSTEIN_E) (OPD)
READ:18-JUN-1996 13:22:26.34

TO: Holly H. Holt (HOLT_H) (WHO)
READ:24-JUN-1996 09:26:31.56

TO: Kimberly J. Hopkins (HOPKIN_K) Autoforward to: Remote Addressee (Kim J. Hopkins@lngate@eopmrx) (VPO)
READ:NOT READ

TO: Stephen K. Horn (HORN_S) (WHO)

READ:18-JUN-1996 14:27:00.01

TO: Russell W. Horwitz (HORWITZ_R) (WHO)
READ:18-JUN-1996 13:22:16.63

TO: Eric P. Hothem (HOTHEM_E) (WHO)
READ:18-JUN-1996 14:26:51.42

TO: Bonnie J. Houchen (HOUCHE_B) Autoforward to: Remote Addressee (Bonnie Houchen@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Laura J. Houseman (HOUSEMAN_L) (OMB)
READ:18-JUN-1996 15:05:04.37

TO: Michelle A. Houston (HOUSTON_M) (WHO)
READ:18-JUN-1996 15:55:32.52

TO: Helen P. Howell (HOWELL_H) (WHO)
READ:18-JUN-1996 14:35:06.09

TO: Carolyn C. Huber (HUBER_C) (WHO)
READ:18-JUN-1996 13:07:57.29

TO: Maureen A. Hudson (HUDSON_M) (WHO)
READ:28-JUN-1996 08:15:57.56

TO: Edward F. Hughes (HUGHES_E) (WHO)
READ:18-JUN-1996 12:53:13.78

TO: Phillip J. Humnicky (HUMNIC_P) Autoforward to: Remote Addressee (Phillip J. Humnicky@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Harold Ickes (ICKES_H) (WHO)
READ:NOT READ

TO: Marilyn R. Jacanin (JACANIN_M) (WHO)
READ:18-JUN-1996 13:28:59.26

TO: Kathryn W. Jackson (JACKSON_KW) (OA)
READ:18-JUN-1996 15:05:56.13

TO: David P. Jacobeen (JACOBEEN_D) (OA)
READ:18-JUN-1996 12:59:14.68

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:21-JUN-1996 08:46:17.59

TO: Thomas C. Jensen (JENSEN_T) (CEQ)
READ:NOT READ

TO: Lionel S. Johns (JOHNS_L) Autoforward to: Remote Addressee (ljohns@ostp.eop.gov@inet) (STP)

READ:NOT READ

TO: Annette E. Johnson (JOHNSON_AE) (WHO)
READ:18-JUN-1996 12:58:52.15

TO: Brian J. Johnson (JOHNSON_BJ) (CEQ)
READ:NOT READ

TO: David T. Johnson (JOHNSON_DT) (NSC)
READ:18-JUN-1996 14:58:04.79

TO: Lee R. Johnson (JOHNSON_LR) (WHO)
READ:27-JUN-1996 12:16:16.59

TO: Robert B. Johnson (JOHNSON_R) (WHO)
READ:NOT READ

TO: Rochester M. Johnson (JOHNSON_RM) (WHO)
READ:18-JUN-1996 18:31:09.37

TO: Wayne C. Johnson (JOHNSON_WC) (OA)
READ:18-JUN-1996 15:38:29.06

TO: Ansley A. Jones (JONES_A) Autoforward to: Remote Addressee (Ansley A. Jones@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Ronald E. Jones (JONES_RE) (OMB)
READ:18-JUN-1996 13:47:11.69

TO: Jennifer A. Jordan (JORDAN_JA) (WHO)
READ:18-JUN-1996 16:15:03.16

TO: R. Lawton Jordan III (JORDAN_RL) Autoforward to: Alison Bracewell (BRACEWELL_A) (WHO)
READ:18-JUN-1996 12:56:49.43

TO: Jennifer O. Jose (JOSE_J) (WHO)
READ:18-JUN-1996 12:56:54.47

TO: M. Kay Joshi (JOSHI_M) (NSC)
READ:18-JUN-1996 14:01:56.77

TO: Gay L. Joshlyn (JOSHLYN_G) (OPD)
READ:18-JUN-1996 14:31:03.19

TO: Lawrence R. Jurcich (JURCICH_L) (OA)
READ:18-JUN-1996 13:57:09.78

TO: Elena Kagan (KAGAN_E) (WHO)
READ:18-JUN-1996 12:59:25.82

TO: David E. Kalbaugh (KALBAUGH_D) (WHO)
READ:18-JUN-1996 13:26:18.33

TO: Thomas A. Kalil (KALIL_T) (WHO)
READ:18-JUN-1996 15:27:14.31

TO: Elaine C. Kamarck (KAMARC_E) Autoforward to: Remote Addressee (Elaine C. Kamarck@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Dorothy L. Karayannis (KARAYANNIS_D)
READ:18-JUN-1996 14:15:57.29

TO: Sally Katzen (KATZEN_S) (OMB)
READ:21-JUN-1996 12:26:45.82

TO: Janice F. Kearney (KEARNEY_J) (WHO)
READ:NOT READ

TO: Timothy J. Keating (KEATING_T) (WHO)
READ:NOT READ

TO: Loreen M. Keller (KELLER_L) (WHO)
READ:19-JUN-1996 09:41:00.82

TO: Henry C. Kelly (KELLY_H) Autoforward to: Remote Addressee (hkelly@ostp.eop.gov@inet) (STP)
READ:NOT READ

TO: Steven Kelman (KELMAN_S) (OMB)
READ:18-JUN-1996 17:05:20.81

TO: Joseph T. Keohan (KEOHAN_J) (VPO)
READ:NOT READ

TO: Charles E. Kieffer (KIEFFER_C) (OMB)
READ:18-JUN-1996 18:37:03.23

TO: Angus S. King (KING_A) (WHO)
READ:18-JUN-1996 13:17:01.66

TO: Joshua A. King (KING_J) (WHO)
READ:18-JUN-1996 13:46:11.12

TO: Nick B. Kirkhorn (KIRKHORN_N) (WHO)
READ:18-JUN-1996 13:00:25.80

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 13:00:51.16

TO: James Kohlenberger (KOHLEN_J) Autoforward to: Remote Addressee (Jim Kohlenberger@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Charles S. Konigsberg (KONIGSBERG_C) (OMB)
READ:18-JUN-1996 14:14:19.60

TO: John A. Koskinen (KOSKINEN_J) (OMB)
READ:18-JUN-1996 13:09:55.13

TO: Lisa Kountoupes (KOUNTOUPES_L) (OMB)
READ:18-JUN-1996 14:44:45.81

TO: Lori K. Krause (KRAUSE_L) (WHO)
READ:18-JUN-1996 15:57:36.58

TO: Heidi Kukis (KUKIS_H) Autoforward to: Remote Addressee (Heidi Kukis@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Karin Kullman (KULLMAN_K) (WHO)
READ:18-JUN-1996 13:04:07.31

TO: Robert D. Kyle (KYLE_R) (OPD)
READ:NOT READ

TO: Tracy B. LaBrecque (LABRECQUE_T) (WHO)
READ:18-JUN-1996 13:53:09.88

TO: Anthony Lake (LAKE_A) (NSC)
READ:NOT READ

TO: Linda L. Lance (LANCE_L) Autoforward to: Remote Addressee (Linda L. Lance@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: G. N. Lattimore (LATTIMORE_G) (WHO)
READ:NOT READ

TO: Jackie D. Lawson (LAWSON_J) (OA)
READ:19-JUN-1996 07:42:26.16

TO: Malcolm R. Lee (LEE_M) (OPD)
READ:NOT READ

TO: Christopher S. Lehane (LEHANE_C) (WHO)
READ:18-JUN-1996 15:59:08.39

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUN-1996 15:29:02.45

TO: Jacob J. Lew (LEW_J) (OMB)
READ:18-JUN-1996 14:12:27.85

TO: Maureen F. Lewis (LEWIS_M) (WHO)
READ:18-JUN-1996 13:08:12.17

TO: Peggy A. Lewis (LEWIS_P) (WHO)
READ:NOT READ

TO: Patricia F. Lewis (LEWIS_PF) (WHO)
READ:18-JUN-1996 14:42:53.36

TO: Gordon Li (LI_G) (WHO)
READ:18-JUN-1996 13:04:34.29

TO: Evelyn S. Lieberman (LIEBERMAN_E) (WHO)
READ:18-JUN-1996 14:44:15.09

TO: Bruce R. Lindsey (LINDSEY_B) (WHO)
READ:19-JUN-1996 10:29:31.01

TO: D. Craig Livingstone (LIVINGSTON_D) (WHO)
READ:19-JUN-1996 09:20:43.64

TO: Jim Loftus (LOFTUS_J) (WHO)
READ:NOT READ

TO: matthew E. Lorin (LORIN_M) (NSC)
READ:20-JUN-1996 10:35:37.10

TO: Jay E. Lowry (LOWRY_J) (NSC)
READ:18-JUN-1996 15:11:50.47

TO: Susanna M. Ludwig (LUDWIG_S) (WHO)
READ:18-JUN-1996 14:02:17.71

TO: Marlene A. MacDonald (MACDONALD_M) (WHO)
READ:18-JUN-1996 15:06:48.22

TO: Mary L. Maddox (MADDOX_M) (WHO)
READ:20-JUN-1996 13:21:12.12

TO: Marna E. Madsen (MADSEN_M) (WHO)
READ:19-JUN-1996 08:50:49.42

TO: Ira C. Magaziner (MAGAZINER_I) (WHO)
READ:18-JUN-1996 13:15:19.22

TO: Alphonse Maldon (MALDON_A) (WHO)
READ:18-JUN-1996 20:56:22.08

TO: Robert Malley (MALLEY_R) (NSC)
READ:NOT READ

TO: Michael D. Malone (MALONE_M) (WHO)
READ:18-JUN-1996 13:55:35.96

TO: Heather M. Marabeti (MARABE_H) Autoforward to: Remote Addressee (Heather M. Marabeti@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Eli Mark (MARK_E) (WHO)
READ:18-JUN-1996 12:53:36.25

TO: David C. Marksz (MARKSZ_D) (WHO)
READ:NOT READ

TO: Thurgood Marshall (MARSHA_T) Autoforward to: Remote Addressee (Thurgood Marshall Jr.@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Capricia P. Marshall (MARSHALL_C) (WHO)
READ:19-JUN-1996 11:12:36.09

TO: Ray Martinez (MARTINEZ_R) (WHO)
READ:18-JUN-1996 13:37:51.35

TO: Julie E. Mason (MASON_J) (WHO)
READ:NOT READ

TO: Michael Massey (MASSEY_M) (WHO)
READ:18-JUN-1996 13:43:05.51

TO: Doris O. Matsui (MATSUI_D) (WHO)
READ:18-JUN-1996 13:03:54.78

TO: Sonyia Matthews (MATTHEWS_S) (OPD)
READ:18-JUN-1996 13:04:26.67

TO: Douglas R. Matties (MATTIES_D) (OA)
READ:18-JUN-1996 12:55:25.92

TO: Clifford J. Mauton (MAUTON_C) (WHO)
READ:18-JUN-1996 12:58:25.11

TO: Natalie L. Mayer (MAYER_N) (WHO)
READ:18-JUN-1996 12:57:57.71

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:18-JUN-1996 12:54:12.83

TO: Mark J. Mazur (MAZUR_M) (WHO)
READ:18-JUN-1996 13:09:08.02

TO: Floydetta McAfee (MCAFEE_F) (WHO)
READ:18-JUN-1996 15:22:44.60

TO: Barry R. McCaffrey (MCCAFFREY_B) (DON)
READ:NOT READ

TO: Colleen A. McCarthy (MCCARTHY_C)
READ:NOT READ

TO: Ellen W. McCathran (MCCATHRAN_E) (WHO)
READ:18-JUN-1996 14:55:06.96

TO: William W. McCathran (MCCATHRAN_W) (WHO)

READ:20-JUN-1996 10:34:23.11

TO: Kelli R. McClure (MCCLURE_K) (WHO)
READ:21-JUN-1996 10:59:29.33

TO: Ann McCoy (MCCOY_A) (WHO)
READ:24-JUN-1996 11:21:11.65

TO: Michael McCurry (MCCURRY_M) (WHO)
READ:NOT READ

TO: Anne E. McGuire (MCGUIRE_A) (WHO)
READ:18-JUN-1996 14:34:47.88

TO: Kara M. McGuire (MCGUIRE_K) (WHO)
READ:NOT READ

TO: Lorraine McHugh (MCHUGH_L) (WHO)
READ:18-JUN-1996 12:54:19.92

TO: Patricia A. McHugh (MCHUGH_P) (WHO)
READ:18-JUN-1996 13:37:12.96

TO: John Y. McInnis (MCINNIS_J) (OA)
READ:25-JUN-1996 10:14:14.31

TO: Brian P. McKaig (MCKAIG_B) (OA)
READ:18-JUN-1996 13:34:01.27

TO: Kathy McKiernan (MCKIERNAN_K) (WHO)
READ:18-JUN-1996 15:22:46.47

TO: Thomas F. McLarty (MCLARTY_T) (WHO)
READ:NOT READ

TO: Thomas P. Mcmahon (MCMAHO_T) Autoforward to: Remote Addressee (Thomas McMahon@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Patricia M. McMahon (MCMAHON_P) (DON)
READ:18-JUN-1996 17:42:28.33

TO: Susan McNay (MCNAY_S) (WHO)
READ:18-JUN-1996 14:16:57.47

TO: Robert W. McNeely (MCNEELY_R) (WHO)
READ:NOT READ

TO: APRIL K. MELLODY (MELLODY_A) (WHO)
READ:18-JUN-1996 13:35:42.39

TO: Manuel A. Mendoza (MENDOZA_M) (WHO)
READ:19-JUN-1996 11:38:13.99

TO: Rosalyn A. Miller (MILLER_RA) (OPD)
READ:19-JUN-1996 09:47:31.69

TO: Cathy L. Millison (MILLISON_C) Autoforward to: M. Kate Friedrich (FRIEDRICH_M) (NSC)
READ:NOT READ

TO: Cheryl D. Mills (MILLS_C) (WHO)
READ:18-JUN-1996 13:29:46.98

TO: Nancy-Ann E. Min (MIN_N) (OMB)
READ:18-JUN-1996 16:08:02.39

TO: Joseph Minarik (MINARIK_J) (OMB)
READ:18-JUN-1996 12:55:23.83

TO: Sharon L. Mitchell (MITCHELL_S) (OA)
READ:18-JUN-1996 16:05:07.96

TO: Elaine M. Mitsler (MITSLER_E) (NSC)
READ:18-JUN-1996 13:20:46.09

TO: Julia Moffett (MOFFETT_J) (WHO)
READ:18-JUN-1996 17:43:25.53

TO: Elizabeth A. Montoya (MONTOYA_E) (WHO)
READ:18-JUN-1996 14:39:23.03

TO: Linda L. Moore (MOORE_L) (WHO)
READ:NOT READ

TO: Jeter A. Morris (MORRIS_J) (GSA)
READ:18-JUN-1996 14:27:51.20

TO: Ruby G. Moy (MOY_R) (WHO)
READ:18-JUN-1996 21:01:26.62

TO: Alicia H. Munnell (MUNNELL_A) (WHO)
READ:18-JUN-1996 12:54:13.36

TO: Janet Murguia (MURGUIA_J) Autoforward to: Annette E. Johnson (JOHNSON_AE) (WHO)
READ:18-JUN-1996 12:58:52.15

TO: Melissa M. Murray (MURRAY_MM) (WHO)
READ:18-JUN-1996 13:19:51.87

TO: Alison Muscatine (MUSCATINE_A) (WHO)
READ:NOT READ

TO: Betsy Myers (MYERS_B) (WHO)
READ:18-JUN-1996 13:12:32.03

TO: Sam Myers (MYERS_S) (WHO)

READ:NOT READ

TO: Alex Nagy (NAGY_A) (WHO)
READ:21-JUN-1996 15:51:15.83

TO: Lucie F. Naphin (NAPHIN_L) (WHO)
READ:18-JUN-1996 13:02:35.26

TO: Steven J. Naplan (NAPLAN_S) (NSC)
READ:18-JUN-1996 12:54:10.69

TO: Bob J. Nash (NASH_B) (WHO)
READ:18-JUN-1996 14:07:05.77

TO: Michael R. Nelson (NELSON_M) Autoforward to: Remote Addressee (mnelson@ccmail.ostp.eop.gov@inet) (STP)
READ:NOT READ

TO: Miriam R. Nemetz (NEMETZ_M) (WHO)
READ:30-JUN-1996 15:16:30.14

TO: Stephen R. Neuwirth (NEUWIRTH_S) (WHO)
READ:NOT READ

TO: Wendy C. New (NEW_W) Autoforward to: Remote Addressee (Wendy C. New@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Timothy L. Newell (NEWELL_T) (STP)
READ:21-JUN-1996 12:33:41.19

TO: Holly B. Nichols (NICHOLS_H) (WHO)
READ:NOT READ

TO: Stephen R. Nolet (NOLET_S) (WHO)
READ:18-JUN-1996 13:52:12.60

TEXT:
MEMORANDUM FOR ALL BLUE PASSHOLDERS
FROM: JODIE R. TORKELSON
ASSISTANT TO THE PRESIDENT FOR
MANAGEMENT AND ADMINISTRATION
SUBJECT: West Wing Tours

West Wing tours will be closed Thursday, June 20 due to official events.
Call the Staff Tour & Information Line (ext 62002) for updates and changes to
the West Wing tour schedule.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:18-JUN-1996 17:11:08.28

SUBJECT: RE: CHR / tomorrow-Conference Call w/ Cong. Woolsey

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUN-1996 17:12:23.04

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 09:40:32.97

CC: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 17:13:52.87

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:24-JUN-1996 17:09:18.24

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUN-1996 17:44:37.18

TEXT:
I would say that that would be helpful -- or, if you want to just email her and ask her if a verbal briefing would do. If this is the case, then you should get here approx. 4:15. She'll be in a 3-4:00 meeting and then back to her office. just let me know if I should expect something from you.
THANKS.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUN-1996 15:56:57.59

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:18-JUN-1996 16:02:48.25

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:NOT READ

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:18-JUN-1996 11:15:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 06/18/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
June 18, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

****

"CDC's Deceitful HIV Scare Campaign"
"In Quests Outside Mainstream, Medical Projects Rewrite Rules"
"Lifeline: Fur's Flying"
"Why Do We Insist on Scaring Our Children?"
"Health Notes: New Convenience in AIDS Drug"
"Ribozyme Pharmaceuticals Gets Preliminary Approval for AIDS Drug Trials"
"More Than 100 Million Worldwide Predicted To Be HIV-Positive by

Year 2000"
"Agency Formed to Coordinate AIDS Vaccine Development"
"Infection and AIDS in Adult Macaques After Nontraumatic Oral Exposure to Cell-Free SIV"
"Japanese Minister Takes Pay Cut to Atone for HIV Contamination"
****

"CDC's Deceitful HIV Scare Campaign"
Wall Street Journal (06/18/96) P. A23; Wright, Michael

In a letter to the editor of the Wall Street Journal, Michael Wright, of Scientific Social Research, criticizes previous letters written by Centers for Disease Control and Prevention officials and former Surgeon General C. Everett Koop. Wright claims that the letter from the CDC, written in defense of the agency's HIV education campaign, falsely claimed that in 1987 the agency did not know that certain groups were at higher risk for HIV than others. Calling those statements "indefensible," he cites a 1987 CDC report and other studies that specifically named high-risk groups and said that people not belonging to any of the groups had a lower risk of contracting HIV. Wright concludes that CDC officials should have recognized this disparity in risk and should be held responsible for the dishonest scare campaign they engineered.

"In Quests Outside Mainstream, Medical Projects Rewrite Rules"
New York Times (06/17/96) P. A1; Kolata, Gina

The Office of Alternative Medicine, part of the National Institutes of Health, was founded in 1991 by Congress to determine the possible benefits of a variety of treatments not accepted by the conventional medical establishment. The office has not yet proven any alternative therapy to work or fail. Its budget is relatively small--$7,486,000 for fiscal year 1996--and some scientists have criticized the office for distributing money to researchers who have little experience with clinical research or clinical trials. A $920,000 grant was awarded to Leanna J. Standish, a neuropath at Bastyr University in Seattle, for a 1,500- to 2,000-person clinical trial evaluating alternative AIDS therapies. Standish hopes to determine which alternative treatments for HIV have the most potential. Richard Peto, a clinical trial expert, said the study would prove useless because, even as an exploratory program, it lacked a control group.

"Lifeline: Fur's Flying"
USA Today (06/18/96) P. 1D; Vigoda, Arlene

Jeff Getty, the AIDS patient and activist that received a baboon bone marrow transplant last year, is joining other AIDS patients in Washington, D.C., this week for a counter-protest against animal rights activists. Getty has criticized People for the Ethical Treatment of Animals and other groups for delaying AIDS research.

"Why Do We Insist on Scaring Our Children?"
USA Today (06/18/96) P. 13A; Medved, Michael

In a commentary on society's warnings to young people, film critic Michael Medved writes in USA Today that the negativism presented by the schools, the media, and parents concerning issues including AIDS, drugs, divorce, and crime is too strong and is undermining children's hope. He says that the trend toward warning children at younger and younger ages is new and is failing. Moreover, the critic points out that despite increased sex education programs, some schools report increases in unprotected sexual activity. Medved advocates optimism for children and says that scare tactics bring about increased self-pity and feelings of victimization.

"Health Notes: New Convenience in AIDS Drug"
United Press International (06/18/96); Milius, Susan

The antibiotic Zithromax can now be taken by HIV-infected individuals once a week rather than every day. The Food and Drug Administration has approved the new dose formulation of the drug that can help prevent Mycobacterium avium complex (MAC) infections in the blood. MAC, which the CDC estimates affects an estimated 25 percent of AIDS patients, causes fever, fatigue, diarrhea, and wasting.

"Ribozyme Pharmaceuticals Gets Preliminary Approval for AIDS Drug Trials"
Knight-Ridder (06/18/96); Locke, Tom

Ribozyme Pharmaceuticals has received approval from an advisory panel at the National Institutes of Health to move forward with plans for a clinical trial for an unnamed AIDS drug. The clinical trial will test a new treatment in which cells would be taken from a patient with HIV, treated with the drug, and then returned to the patient. The first phase of the trial may begin within a few months.

"More Than 100 Million Worldwide Predicted To Be HIV-Positive by Year 2000"
Reuters (06/17/96)

A researcher at the University of Maryland Institute of Human Virology in Baltimore estimates that 20 million people worldwide are currently infected with HIV and that 100 million people will have the virus by the year 2000. William Blattner reports that the pattern of HIV infection has shifted quickly and that more than 90 percent of those infected with HIV in the year 2000 will be in developing countries. In the June 1 issue of Internal Medicine News, he projects that the pandemic will become more prevalent in Asia than in Africa over the coming years.

"Agency Formed to Coordinate AIDS Vaccine Development"
Reuters (06/17/96)

The International AIDS Vaccine Initiative, sponsored by the Rockefeller Foundation, was founded to work with non-profit, profit, and government groups to make AIDS vaccine research less risky for private-sector investors. The agency was described in the June 15 issue of the Lancet. Peggy Johnston, scientific director of the project, said the initiative will support

research and development aimed at filling in gaps of current programs. She noted that it is especially important to consider the high prevalence of HIV infection in developing countries and to develop vaccines that target different HIV strains.

"Infection and AIDS in Adult Macaques After Nontraumatic Oral Exposure to Cell-Free SIV"
Science (06/07/96) Vol. 272, No. 5267; P. 1486; Baba, Timothy W.; Trichel, Anita M.; An, Li; et al.

Reported cases of HIV-1 transmission by oral-genital exposure have been rare, and a quantitative assessment of the relative HIV risk of oral infection has not been possible. Infection of rhesus monkeys with SIV is the best system to model human HIV-1 transmission, viremia, and disease. Ruth M. Ruprecht, of the Dana-Farber Cancer Institute, and others exposed two rhesus monkeys to SIV orally, and both became infected. The researchers found that the minimum amount of virus required for infection from oral exposure was 6,000 times lower than that needed for rectal infection. They therefore suggest that infection from intrarectal exposure in humans is more common than infection from oral-genital exposure because rectal infection is facilitated by mucosal tears during sexual intercourse. According to the researchers, the findings do not imply that HIV-1 transmission is likely to occur through casual contact or that the risk for oral infection is limited to high viral levels, as found in blood or semen. The portal of virus entry after oral exposure should be studied further, the researchers suggest, noting that unprotected oral sex should be considered a risk behavior for HIV-1 transmission.

"Japanese Minister Takes Pay Cut to Atone for HIV Contamination"
Nature (06/06/96) Vol. 380, No. 6582; P. 460

Japan's Health and Welfare Minister Naoto Kan has announced that he and vice-minister Hiroshi Tada will take a 20 percent reduction in pay over the next two months in an attempt to atone for the government's role in the tainted blood scandal in the early- to mid-1980s. Kan only became minister in January, so he bears no responsibility for the disaster, which resulted in 2,000 Japanese hemophiliacs becoming infected with HIV from non-heat-treated blood products. He led efforts to expose the ministry's role in the scandal, but, according to Japanese tradition, Kan should take symbolic responsibility. Representatives of hemophiliacs were not satisfied with the action, saying the pay cut is not adequate atonement for the infection of so many people.

========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========
ATT CREATION TIME/DATE:18-JUN-1996 11:15:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I61VUJPOM8018VH0@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Tue, 18 Jun 1996 11:12:27 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I61VYRIEY600007X@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Tue, 18 Jun 1996 11:15:51 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA02609; Tue,
18 Jun 1996 11:15:00 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 2 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUN-1996 17:12:19.84

SUBJECT: RE: CHR / tomorrow-Conference Call w/ Cong. Woolsey

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUN-1996 17:17:33.88

TEXT:
it will be there in a few minutes

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:18-JUN-1996 16:34:59.56

SUBJECT: CHR / tomorrow-Conference Call w/ Cong. Woolsey

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 09:37:14.85

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUN-1996 16:43:59.69

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 17:02:36.41

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:24-JUN-1996 17:08:51.11

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUN-1996 17:45:53.02

TEXT:

Patsy/Jeff/Jennifer:
we've scheduled a conference call for CHR w/ Cong. Woolsey - at Woolsey's request, to discuss a bill that she'll a medical foods bill that she'll be introducing. Woolsey's scheduler said something about AIDS patients using medicare for medical foods.
CHR would like Patsy or Jeff to sit in on the conference call w/ her - it's scheduled for 4:30 p.m.
Jen: CHR asked whether or not you or Chriss Jennings should sit in as well?
I received something from their office and will fax to Patsy/Jeff and will walk over to Jen.
I understand Patsy will be leaving on a trip -- can we confirm Jeff to be here by 4:25?
please let me know, thanks! JIll.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUN-1996 17:31:51.58

SUBJECT: Background on Woolsey call

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:18-JUN-1996 17:34:45.56

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 09:40:53.14

CC: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 17:33:38.05

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:18-JUN-1996 20:49:27.25

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUN-1996 17:44:24.66

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUN-1996 19:58:55.56

CC: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUN-1996 17:49:00.74

TEXT:
The medical foods bill -- requiring FEHBP to cover them for people with AIDS -- is a solution looking for a problem. But here's the story:
Patsy has met with Woolsey and she promised that we would work with OPM to try to address this administratively as well as to work with HCFA to make sure that all the states were covering medical foods for their Medicaid clients. This is also a recommendation of the Advisory Council. It seems that the push for inclusion under FEHBP is designed to set a precedent to move some of the private carriers outside of FEHBP to cover this product.
To our knowledge, it is not a problem for individuals to get medical foods covered under their FEHBP plans. OPM has received no complaints to this effect. OPM formally commented in opposition to this legislation, feeling (correctly) that we should not legislate coverage of specific products. This would truly be a slippery slope. However, OPM is also extremely reluctant to administratively require coverage of specific products given their "flexible services" approach. (In this year's call for contracts, they did mention medical foods as an example of a service that could be covered under flexible services.)
Here's what we have done:
(1) HCFA is sending a letter to all state Medicaid directors --

probably by the end of the week -- discussing both protease inhibitors and medical foods -- reminding them that these products are part of the current standard of care (and therefore should be covered).

(2) We have found a way out of OPM's reluctance to mandate coverage of a specific product -- they are currently in the final stages of clearance for a letter from OPM to Patsy stating that their flexible services plan is intended to cover medical foods and that anyone having a problem with getting coverage of medical foods should contact OPM so they can work with his/her carrier to resolve the problem. They will send a copy of this letter with a cover note to all of the FEHBP carriers. (This, somehow, is acceptable to them, whereas a direct letter to the carriers is not. It seems to be a distinction without a difference, but then I haven't worked at OPM for 30 years.)

I think this would do the trick of accomplishing adminstratively what Woolsey wants to do legislatively. When we have the OPM letter in hand, we are happy to talk with Woolsey about releasing it in a way to give her credit for having raised the issue.

Hope this is helpful. Let me know if you need more information.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:18-JUN-1996 17:36:36.79

SUBJECT: RE: Background on Woolsey call

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:19-JUN-1996 07:23:50.64

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 10:07:48.08

CC: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUN-1996 17:40:31.81

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:18-JUN-1996 20:49:52.15

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUN-1996 17:44:15.50

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUN-1996 19:59:02.85

CC: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUN-1996 18:05:25.99

TEXT:
So what can we tell her, not tell her tomorrow afternoon in the call?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUN-1996 15:54:19.38

SUBJECT: september meeting

TO: Remote Addressee (KSF@s-3.com@INET@EOPMRX)
READ:NOT READ

CC: Remote Addressee (ScottHitt@aol.com@INET@EOPMRX)
READ:NOT READ

TEXT:
any news about where we are on the September meeting date and
site?

Withdrawal/Redaction Marker
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Jeffrey Levi, To: Jill Pizzuto, Re: Today, 6:00 PM (1 page)	06/18/1996	Personal Misfile

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
002. email	From: Jeffrey Levi, To: Dorothy Karayannis, Re: I am told this is not a surprise (1 page)	06/18/1996	Personal Misfile

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 16:10:49.56

SUBJECT: Sherlyl Sutler Darden

TO: Remote Addressee (cjb4@cpsod1.em.cdc.gov@INET)
READ:NOT READ

TEXT:
Effective June 4, 1996, Sheryl Sutler Darden has served as the Agency Representative of the Centers for Disease Control to the White House Office of National AIDS Policy. She works in support of the Interdepartmental Task Force (IDTF) on HIV/AIDS. The IDTF is the coordinating body for HIV/AIDS activities across the Federal government.
Ms. Darden's duties include, but are not limited to:
(1) Development of the Ntaional Strategy on HIV/AIDS, with special focus on the prevention component.
(2) Working with the prevention-related agencies of the IDTF.
(3) Providing support for the prevention subcommittee of the Presidential Advisory Council on HIV/AIDS.
(4) Serving as liaison between the White House Office of National AIDS Policy and the CDC, SAMHSA, and other agencies in response to the President's directive for closer linkages between HIV prevention and substance abuse programs.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 18:29:59.21

SUBJECT: Re: this is a test

TO: Margaret Chesney (Margaret_Chesney@quickmail.ucsf.edu@INET@EOPMRX)
READ:NOT READ

TEXT:
Indeed, it did work. Assuming we are moving forward...I am going to be in SF on July 1 and 2 for a Keystone Center dialogue on clinical effectiveness research. I am free on July 1 until 1 p.m. or on July 2 after 3:30 p.m.....do you want to set a tentative time now? thanks.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:19-JUN-1996 17:47:00.00

SUBJECT: interview questions

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:19-JUN-1996 17:56:19.83

TO: CALVIN ADAMS (CADAMS@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
Please e mail your interview questions to me at your earliest convenience to coordinate. Time is critical and the interviews are around the corner.
Calvin-diversity
Jeff-strategic vision
Bill-relationships with outside agencies, balance with other programs in Bureaus
This would be easier than me trying to come up with something. Thanks!

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:19-JUN-1996 17:50:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I63NXL6F5C000960@PMDF.EOP.GOV> for LEVI_J@a1.eop.gov; Wed, 19 Jun 1996 17:47:25 -0400 (EDT)
Received: from PCC.SSW.DHHS.GOV (ibm.pcc.dhhs.gov)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I63O1RZ70S00007X@STORM.EOP.GOV> for LEVI_J@A1.EOP.GOV; Wed, 19 Jun 1996 17:50:00 -0700 (MST)
Received: from HRSA.SSW.DHHS.GOV by PCC.SSW.DHHS.GOV (Soft*Switch Central V4L380P7) id 471348170096171FHRSA; Wed, 19 Jun 1996 17:40:17 -0400 (EDT)
Comment: MEMO 1996/06/19 17:52
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 16:12:19.21

SUBJECT: ADAP

TO: William G. White (WHITE_W) (OMB)
READ:19-JUN-1996 16:14:40.11

TEXT:
Tim Westmoreland has been having one of his law students look at the issue of whether ADAP can pay for thingsl ike viral burden testing. Their preliminary conclusion is that ADAP can pay for related services. If this is the case, we may not have to do this stretching regarding the earmarks. Tim is supposed to bring me a memo on this tomorrow -- and if OMB lawyers agree -- we should sit down with HRSA so they clarify this with their grantees.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Patsy Fleming (FLEMING_P) (WHO)

CREATION DATE/TIME:19-JUN-1996 14:01:03.51

SUBJECT: Misc.

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:19-JUN-1996 14:02:13.95

TEXT:
I have asked to have lunch with Donna for an informal meeting. I want to brief her on UNAIDS, samhsa, etc. Think about other issues I should bring up.

Withdrawal/Redaction Marker
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
003. email	From: DOBER@HRSA.SSW.DHHS.GOV, To: Multiple Recipients, Re: Interviews for Dir, Bureau of Hlth Res Div [partial] (1 page)	06/19/1996	b(6)

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:19-JUN-1996 17:08:00.00

SUBJECT: interviews for Dir, Bureau of Hlth Res Dev

TO: Barbara Garcia (BGARCIA@SAMHSA.GOV@INET@EOPMRX)
READ:NOT READ

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:19-JUN-1996 17:53:33.35

TO: Deborah A. Willis (DWILLIS@PHSCHI.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: Audrey H. Nora (ANORA@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: Deborah Parham (DPARHAM@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: CALVIN ADAMS (CADAMS@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: DENNIS MALCOMSON (DMALCOMS@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
Tuesday, June 25

1000

1130 [003]

(b)(6)

200

330

I have requested references and will forward upon receipt. Please
book your calendars. This will be in Pklwn Rm 18-05.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:19-JUN-1996 17:11:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I63ML6TMY80007Y0@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 19 Jun 1996 17:08:24 -0400 (EDT)
Received: from PCC.SSW.DHHS.GOV (ibm.pcc.dhhs.gov)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I63MOGJ19000007X@STORM.EOP.GOV> for LEVI_J@A1.EOP.GOV; Wed, 19 Jun 1996 17:11:02 -0700 (MST)
Received: from HRSA.SSW.DHHS.GOV by PCC.SSW.DHHS.GOV (Soft*Switch Central V4L380P7) id 540209170096171FHRSA; Wed, 19 Jun 1996 16:59:16 -0400 (EDT)
Comment: MEMO 1996/06/19 17:13
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 07:30:07.92

SUBJECT: POTUS memo

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:19-JUN-1996 11:13:26.64

TEXT:
PRINTER FONT 12_POINT_COURIER
Jane--
Ignore the time that this is being sent. This is a quick draft -- it is a little too long. It seemed easier, however, to give NIH something to respond to than asking for them to start the process -- especially since the space for science in here is so limited. I'm also leaving this for Bopper to look at.

jl

\d

DRAFT MEMORANDUM FOR THE PRESIDENT
FROM: Carol H. Rasco, Assistant to the President for Domestic Policy
Patricia S. Fleming, Director, Office of National AIDS Policy
SUBJECT: New AIDS treatments
There has been considerable press attention recently to the promise offered by a new class of AIDS drugs called protease inhibitors. Because of their tremendous potential, these drugs have been licensed by the FDA under accelerated approval policies, coming to market in record time -- as short as xx days for one of the four protease inhibitors.
These drugs have the capacity to suppress the replication of HIV to almost undetectable levels for a significant period of time. If replication of HIV can be held in check, there is much greater hope that HIV can soon be treated as a chronic disease, rather than a life

-threatening disease. The effect of these protease inhibitors is greatest when taken in combination with other drugs, such as AZT. It is believed that finding the right combination taken early enough in the HIV infection process might even result in eradication of the virus in some individuals, though his has not yet been proven.
It is hard to describe the sense of hope and optimism that has been restored among people living with HIV. This enthusiasm is also felt within the scientific community. But it is important to remember that this is based on short

-term results. We do not
yet know the durability of this effect and its actual impact on reducing mortality among people with HIV. Nor do we know the answers to some very important clinical questions relating to the most effective use of these drugs -- such as when in the course of HIV infection is the best time to start therapy, how long individuals should be treated, what is the optimal combination of drugs, and when one might need to change therapies should resistance develop.
These are issues that the Vice President raised with the pharmaceutical industry as part of his charge from you to work with them to increase their commitment to AIDS research. He has asked the Keystone Center to conduct a policy dialogue among government officials, industry representatives, AIDS advocates, scientists, and third party payers to develop an initial series

of clinical effectiveness questions that must be answered with regard to these new drugs and to propose an on

-going mechanism
for addressing clinical effectiveness questions as AIDS therapies develop.
The NIH has committed to answering these clinical effectiveness questions as rapidly as possible. This capacity to respond to emerging scientific questions underscores the importance of our support for the enhanced programmatic and budget authority of the NIH Office of AIDS Research.
We are also committed to assuring that the benefits of our $1.4 billion annual investment in AIDS research are translated into access to care for people with AIDS. These new drugs are expensive; the cost of these new combination therapies can be as high as $10

-12,000 a year, which reinforces the importance of
clinical effectiveness research into how best to use these new treatment regimens.
On the same day that the FDA approved the first protease inhibitor, you sent to Congress a $52 million FY 1996 budget amendment increasing funding for the AIDS Drug Assistance Program, bringing to $142 million the Federal commitment to this program. This was included in the final continuing resolution.
This week (insert date), HCFA has sent a letter to all state Medicaid directors informing them that treatment with protease inhibitors is now the standard of care, creating the expectation that states must include them in their formularies. (As you know, Medicaid covers nearly 50 percent of people with AIDS.) As it has become clearer that these drugs are going to be widely used, we are also working with OMB to identify still more funding in FY 1997 for the AIDS Drug Assistance Program.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 13:29:57.66

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 13:54:13.68

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:NOT READ

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:19-JUN-1996 11:39:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 06/19/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
June 19, 1996

****

"U.S. Beefs up CDC's Capabilities"
"Brief Report: Rifampin-Resistant Tuberculosis in a Patient Receiving Rifabutin Prophylaxis"
"Blood Samples Called Safe for Mail Handlers"
"HIV/AIDS Clinical Trials Videotape Package Now Available"
****

"40,000 New AIDS Cases Recorded in Zimbabwe"
Xinhua News Agency (06/19/96)

In Zimbabwe, at least 40,000 new AIDS cases were reported last year, the National AIDS Coordination Program said. The agency added that the actual number could be greater than 40,000 and that the estimated total cases could be as high as 150,000. The agency also reported an increase in tuberculosis cases, with more than 22,000 reported from January to September of 1995, compared to 17,000 during the same period in 1994. More than 1 million people in Zimbabwe are believed to be infected with HIV, out of a population of 10.5 million.

"HIV Prevention in Asia: A Business Opportunity"
Reuters (06/18/96)

In a commentary in this week's issue of the Lancet, Ann Marie Kimball of the University of Washington at Seattle and Myo Thant, an economist at the Asian Development Bank in Manila, suggest that the Asian business community should join the fight against the spread of HIV. The authors say that because businesses stand to lose many valuable workers to the epidemic, they should help to increase AIDS awareness and HIV prevention education.

"Risks Quantified for Neoplasms in Children With AIDS"
Reuters (06/18/96)

Unlike adults with AIDS, children with the disease are more likely to get non-Hodgkin's lymphoma than Kaposi's sarcoma, researchers say. This agrees with incidence rates of the cancers in the general pediatric population, however. Diego Serraino and Silvia Franceschi of the Aviano Cancer Center in Aviano, Italy, based their conclusions, reported recently in the journal AIDS, on cases of almost 11,000 children and adolescents with AIDS. Both Kaposi's sarcoma and non-Hodgkin's lymphoma were found more often at AIDS diagnosis in U.S. children than in European children. Overall, 0.4 percent of the children, and 2.7 percent of the adolescents, had Kaposi's sarcoma at AIDS diagnosis. Non-Hodgkin's lymphoma was reported in 0.9 percent of the children in Europe and 1.5 percent of the children in the United States. The researchers also found a higher incidence of Kaposi's sarcoma in adolescents with AIDS who reported homosexual intercourse with other males.

"Namibia to Promote AIDS Program"
Xinhua News Agency (06/18/96)

A team of officials from the government, non-government organizations, the United Nations joint program on AIDS, and the European Union has been assembled to review Namibia's AIDS program

and to promote its implementation. In Namibia, the number of people infected with HIV rose from four in 1986 to 21,737 in April 1996. An estimated 20 percent increase in infections from 1995 to 1996 is expected by the end of the year, National AIDS Control Program Chairman Markus Sivute said. Nine percent of all deaths in the country last year were attributed to AIDS.

"Zambian President Praises NGOs' AIDS Fight"
Africa News Service (06/18/96) ; Phiri, Reuben

Zambian President Frederick Chiluba praised non-governmental organizations (NGOs) on Tuesday for their part in fighting the spread of AIDS. In a speech read on his behalf at the opening of the sixth NGO AIDS Conference, he said that because NGOs are grass roots-based, they are an effective channel of communication between the people being targeted, donor agencies, and the government. Chiluba promised that the government would "make AIDS a top priority for external resource allocation so that Africa benefits from the maximum international cooperation and solidarity in overcoming the epidemic and its impact." Dr. Clarence Mini, chairperson of the Southern African Network of AIDS Services Organizations, asked the government to re-affirm its pledge to ensure that everyone is educated about AIDS and HIV prevention.

"Atovaquone Effective Against Microsporidiosis in HIV-Positive Patients"
Reuters (06/18/96)

Atovaquone may be a potential alternative treatment for gastrointestinal microsporidiosis, a common cause of chronic diarrhea, wasting, and death in patients with advanced AIDS, researchers report in the journal AIDS. Jeffrey L. Lennox of Emory University and colleagues found that of 22 HIV-infected patients with intestinal microsporidial infection, the most common agent causing diarrhea was Enterocytozoon bieneusi. There is no generally accepted treatment for E. bieneusi infection, but the researchers found that atovaquone was effective against the patients' diarrhea. The treatment, however, did not decrease the parasite burden in most patients.

"Zimbabwe to Reduce STDs"
Xinhua News Agency (06/18/96)

In Zimbabwe, a country with 10.5 million residents, more than 39 million condoms were distributed in 1995, according to the National AIDS Coordination Program. Only 25.6 million condoms were distributed in 1994. The agency said that the control of sexually transmitted diseases is a key to the prevention of sexual HIV transmission. More than 1 million of the country's citizens are thought to be infected with HIV, and an estimated 300 are dying each week from AIDS-related diseases.

"U.S. Beefs Up CDC's Capabilities"
Science (06/07/96) Vol. 272, No. 5267; P. 1413; Pennisi, Elizabeth

In 1967, health officials in the United States and other developed countries thought they were on their way to conquering

infectious diseases with vaccines and antibiotics. However, now tuberculosis, cholera, and other diseases previously under control have re-emerged, and, along with AIDS and other new infections, caused deaths in the United States from infectious diseases to increase by 58 percent between 1980 and 1992. Officials at the Centers for Disease Control and Prevention concede that they became complacent and two years ago began taking steps to become more vigilant. A $125-million plan was proposed, calling for increased monitoring for emerging infections, improvements in local and state public health facilities, and enhanced international efforts. Congress allocated $6.7 million for the effort in 1995 and $10.7 million this year, and President Clinton wants to increase the amount to $27 million in 1997. The CDC has also said it will provide $200,000 a year to 13 states, as well as to New York City and Los Angeles, to improve their efforts against disease. Experts say that the funding pledged is not sufficient for preventing problems and will likely be used to deal with crises rather than the more cost-effective method of catching outbreaks early and preventing the spread of an epidemic.

"Brief Report: Rifampin-Resistant Tuberculosis in a Patient Receiving Rifabutin Prophylaxis"
New England Journal of Medicine (06/13/96) Vol. 334, No. 24; P. 1573; Bishai, William R.; Graham, Neil M.H.; Harrington, Susan; et al.

Drug-resistant tuberculosis (TB) is a growing problem in the United States, and resistance to rifampin, a popular TB prophylactic drug for HIV-infected patients, is especially threatening. Nine percent of TB cases in New York City in 1991 were rifampin-resistant, up from less than 1 percent in 1979. Furthermore, prophylactic use of rifabutin, introduced in 1993, may induce rifampin-resistant TB. Dr. William R. Bishai, of Johns Hopkins University, and colleagues present the case of a 35-year-old man with HIV who was hospitalized and treated for TB. He was cleared of M. tuberculosis after six months of treatment, including treatment with rifampin. The patient then began seeing a private doctor and began taking rifabutin as prophylaxis against TB. Two months later, the patient developed symptoms of TB and died; a strain of M. tuberculosis resistant to rifampin and rifabutin was found to be the cause. The man's first and second episodes of TB were caused by strains that were identical except that the second one was resistant to rifabutin and rifampin. The researchers conclude that it is important to screen all patients for active TB before starting rifabutin prophylaxis, as is recommended by the Public Health Service.

"Blood Samples Called Safe for Mail Handlers"
Federal Times (06/10/96) Vol. 32, No. 18; P. 10; Bridger, Chet

Following the recent approval of the country's first mail-in HIV test kit comes approval for postal workers to carry the blood samples. Both the U.S. Postal Service and Johnson & Johnson, the maker of the Confide HIV test, said carrying the packages was not a health risk for postal workers. The Confide

sample to be mailed consists of three dried blood spots on a card. The card will be sealed in a plastic container, sealed in a cardboard container, sealed inside a shipping box. The boxes will be handled manually and will be labeled as clinical specimens, carrying a green border that identifies them as HIV tests. All packages will be sent to Laboratory Corporation of America near Bridgewater, N.J. Johnson & Johnson says the kits could account for more than 5 million pieces of mail next year. The test kit will be available in Texas and Florida this summer and will be offered nationwide in 1997.

"HIV/AIDS Clinical Trials Videotape Package Now Available"
AIDS Clinical Trials Information Service (ACTIS) (06/18/96)

The new HIV/AIDS Clinical Trials: Knowing Your Options videotape package is now available from the AIDS Clinical Trials Information Service (ACTIS). ACTIS is a national information and referral service that provides the latest details on federally and privately sponsored clinical trials for experimental drugs and other HIV-related therapies for adults and children. The HIV/AIDS Clinical Trials: Knowing Your Options package includes a VHS videotape, a discussion leader's guide, and a brochure. The 19-minute videotape clearly explains what HIV/AIDS clinical trials are and presents a simple "Learn, Consider, and Choose" approach for making personal decisions related to trials. The video features interviews with people who have participated in clinical trials as well as doctors and nurses who work in medical research programs. The HIV/AIDS Clinical Trials: Knowing Your Options package and additional copies of the brochure can be ordered from ACTIS (1-800-874-2572). There are nominal fees for the video package and extra brochures to cover shipping and handling costs. The videotape package costs $15 and extra brochures are 10> per copy. Discounts are available for bulk orders.

========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========
ATT CREATION TIME/DATE:19-JUN-1996 11:40:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
 by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I63B0HWT1C00010Z@PMDF.EOP.GOV> for
 levi_j@a1.eop.gov; Wed, 19 Jun 1996 11:37:10 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
 by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I63B3UBGI400007X@STORM.EOP.GOV> for
 levi_j@a1.eop.gov; Wed, 19 Jun 1996 11:39:50 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA18579; Wed,
 19 Jun 1996 11:39:00 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

========== END ATTACHMENT 2 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 15:56:25.38

SUBJECT: RE: congressional mailing list

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:19-JUN-1996 16:04:04.57

TEXT:
oh boy...they're going to want to see this mailing first...so
tread gently....start with Tracey Thornton 456-6493.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Margaret_Chesney@quickmail.ucsf.edu@INET@EOPMRX

CREATION DATE/TIME:19-JUN-1996 18:23:00.00

SUBJECT: Re: this is a test

TO: Jeffrey Levi (LEVI_J@A1@CD)(WHO)
READ:19-JUN-1996 18:30:21.85

TEXT:
It worked!!!

Date: 6/19/96 3:29 PM
To: Margaret Chesney
From: Jeffrey Levi
let's see if this works.

---------- RFC822 Header Follows ----------
Received: by quickmail.ucsf.edu with SMTP;19 Jun 1996 15:27:16 -0800
Received: from pmdf.eop.gov by gatekeeper.eop.gov;
(5.65v3.2/1.1.8.2/17Oct95-0424PM)
id AA05166; Wed, 19 Jun 1996 18:18:09 -0400
Received: from mr.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)
id <01I63OWZYWOW0009KD@PMDF.EOP.GOV> for Margaret_Chesney@quickmail.ucsf.edu;
Wed, 19 Jun 1996 18:15:15 -0400 (EDT)
Received: with PMDF-MR; Wed, 19 Jun 1996 18:17:27 -0400 (EDT)
Mr-Received: by mta DALE; Relayed; Wed, 19 Jun 1996 18:17:27 -0400
Mr-Received: by mta EOPMRX; Relayed; Wed, 19 Jun 1996 18:15:09 -0400
Alternate-Recipient: prohibited
Date: Wed, 19 Jun 1996 18:17:03 -0400 (EDT)
From: Jeffrey Levi <LEVI_J@a1.eop.gov>
Subject: this is a test
To: Margaret_Chesney@quickmail.ucsf.edu
Message-Id: <E1339ZWIWQ5991*/R=CD/R=A1/U=LEVI_J/@MHS.eop.gov>
Mime-Version: 1.0
Content-Type: TEXT/PLAIN; CHARSET=US-ASCII
Content-Transfer-Encoding: 7BIT
Posting-Date: Wed, 19 Jun 1996 18:17:00 -0400 (EDT)
Importance: normal
Priority: normal
Ua-Content-Id: E1339ZWIWQ5991
X400-Mts-Identifier: [;72718191606991/2671418@CD]
A1-Type: MAIL
Hop-Count: 2

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:19-JUN-1996 18:26:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I63P78J12O0009RO@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Wed, 19 Jun 1996 18:23:26 -0400 (EDT)
Received: from itsa.ucsf.EDU by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <01I63PAJ9O1E00007X@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Wed,
19 Jun 1996 18:26:06 -0700 (MST)
Received: from quickmail.ucsf.edu (qmgtwy2.ucsf.EDU [128.218.80.208])
by itsa.ucsf.EDU (8.6.8/GSC4.24) with SMTP id PAA175530 for
<LEVI_J@a1.eop.gov>; Wed, 19 Jun 1996 15:25:12 -0700
X-Mailer: Mail*Link SMTP-QM 3.0.2
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:19-JUN-1996 15:53:51.91

SUBJECT: congressional mailing list

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:19-JUN-1996 15:56:27.55

TEXT:
Jeff --
Who's the best person at the WH to contact to get an electronic copy of Congressional representatives? It's for the Congressional mailing.
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Patsy Fleming (FLEMING_P) (WHO)

CREATION DATE/TIME:19-JUN-1996 13:58:51.09

SUBJECT: Chavez Meeting 6?25

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:19-JUN-1996 14:01:52.16

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:24-JUN-1996 09:32:26.94

TEXT:
Lets prepare well for this meeting.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Patsy Fleming (FLEMING_P) (WHO)

CREATION DATE/TIME:19-JUN-1996 14:05:05.47

SUBJECT: another thing

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:19-JUN-1996 14:25:41.92

TEXT:
Marilyn Davis (HUD) called to say the agreement was only for FY96 and that it would be no problem to extend it to 97. It only requires some paperwork.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 15:56:47.68

SUBJECT: Rachel Block is now at 2 on Monday

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:19-JUN-1996 16:04:23.92

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 18:17:19.90

SUBJECT: this is a test

TO: Remote Addressee (Margaret_Chesney@quickmail.ucsf.edu@INET@EOPMRX)
READ:NOT READ

TEXT:
let's see if this works.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:19-JUN-1996 11:37:00.00

SUBJECT: CDC AIDS Daily Summary 06/19/96

TO: levi_j (levi_j@A1@CD) (WHO)
READ:19-JUN-1996 13:29:04.25

TEXT:

AIDS Daily Summary
June 19, 1996

****

****

"40,000 New AIDS Cases Recorded in Zimbabwe"
Xinhua News Agency (06/19/96)

In Zimbabwe, at least 40,000 new AIDS cases were reported last year, the National AIDS Coordination Program said. The agency added that the actual number could be greater than 40,000 and that the estimated total cases could be as high as 150,000. The agency also reported an increase in tuberculosis cases, with more than 22,000 reported from January to September of 1995, compared to 17,000 during the same period in 1994. More than 1 million people in Zimbabwe are believed to be infected with HIV, out of a population of 10.5 million.

"HIV Prevention in Asia: A Business Opportunity"
Reuters (06/18/96)

In a commentary in this week's issue of the Lancet, Ann Marie Kimball of the University of Washington at Seattle and Myo Thant, an economist at the Asian Development Bank in Manila, suggest that the Asian business community should join the fight against the spread of HIV. The authors say that because businesses stand to lose many valuable workers to the epidemic, they should help to increase AIDS awareness and HIV prevention education.

"Risks Quantified for Neoplasms in Children With AIDS"
Reuters (06/18/96)

Unlike adults with AIDS, children with the disease are more likely to get non-Hodgkin's lymphoma than Kaposi's sarcoma, researchers say. This agrees with incidence rates of the cancers in the general pediatric population, however. Diego Serraino and Silvia Franceschi of the Aviano Cancer Center in Aviano, Italy, based their conclusions, reported recently in the journal AIDS, on cases of almost 11,000 children and adolescents with AIDS. Both Kaposi's sarcoma and non-Hodgkin's lymphoma were found more often at AIDS diagnosis in U.S. children than in European children. Overall, 0.4 percent of the children, and 2.7 percent of the adolescents, had Kaposi's sarcoma at AIDS diagnosis. Non-Hodgkin's lymphoma was reported in 0.9 percent of the children in Europe and 1.5 percent of the children in the United States. The researchers also found a higher incidence of Kaposi's sarcoma in adolescents with AIDS who reported homosexual intercourse with other males.

"Namibia to Promote AIDS Program"
Xinhua News Agency (06/18/96)

A team of officials from the government, non-government organizations, the United Nations joint program on AIDS, and the European Union has been assembled to review Namibia's AIDS program and to promote its implementation. In Namibia, the number of people infected with HIV rose from four in 1986 to 21,737 in April 1996. An estimated 20 percent increase in infections from 1995 to 1996 is expected by the end of the year, National AIDS Control Program Chairman Markus Sivute said. Nine percent of all deaths in the country last year were attributed to AIDS.

"Zambian President Praises NGOs' AIDS Fight"
Africa News Service (06/18/96) ; Phiri, Reuben

Zambian President Frederick Chiluba praised non-governmental organizations (NGOs) on Tuesday for their part in fighting the spread of AIDS. In a speech read on his behalf at the opening of the sixth NGO AIDS Conference, he said that because NGOs are grass roots-based, they are an effective channel of communication between the people being targeted, donor agencies, and the government. Chiluba promised that the government would "make AIDS a top priority for external resource allocation so that Africa benefits from the maximum international cooperation and solidarity in overcoming the epidemic and its impact." Dr. Clarence Mini,

chairperson of the Southern African Network of AIDS Services Organizations, asked the government to re-affirm its pledge to ensure that everyone is educated about AIDS and HIV prevention.

"Atovaquone Effective Against Microsporidiosis in HIV-Positive Patients"
Reuters (06/18/96)

Atovaquone may be a potential alternative treatment for gastrointestinal microsporidiosis, a common cause of chronic diarrhea, wasting, and death in patients with advanced AIDS, researchers report in the journal AIDS. Jeffrey L. Lennox of Emory University and colleagues found that of 22 HIV-infected patients with intestinal microsporidial infection, the most common agent causing diarrhea was Enterocytozoon bieneusi. There is no generally accepted treatment for E. bieneusi infection, but the researchers found that atovaquone was effective against the patients' diarrhea. The treatment, however, did not decrease the parasite burden in most patients.

"Zimbabwe to Reduce STDs"
Xinhua News Agency (06/18/96)

In Zimbabwe, a country with 10.5 million residents, more than 39 million condoms were distributed in 1995, according to the National AIDS Coordination Program. Only 25.6 million condoms were distributed in 1994. The agency said that the control of sexually transmitted diseases is a key to the prevention of sexual HIV transmission. More than 1 million of the country's citizens are thought to be infected with HIV, and an estimated 300 are dying each week from AIDS-related diseases.

"U.S. Beefs Up CDC's Capabilities"
Science (06/07/96) Vol. 272, No. 5267; P. 1413; Pennisi, Elizabeth

In 1967, health officials in the United States and other developed countries thought they were on their way to conquering infectious diseases with vaccines and antibiotics. However, now tuberculosis, cholera, and other diseases previously under control have re-emerged, and, along with AIDS and other new infections, caused deaths in the United States from infectious diseases to increase by 58 percent between 1980 and 1992. Officials at the Centers for Disease Control and Prevention concede that they became complacent and two years ago began taking steps to become more vigilant. A $125-million plan was proposed, calling for increased monitoring for emerging infections, improvements in local and state public health facilities, and enhanced international efforts. Congress allocated $6.7 million for the effort in 1995 and $10.7 million this year, and President Clinton wants to increase the amount to $27 million in 1997. The CDC has also said it will provide $200,000 a year to 13 states, as well as to New York City and Los Angeles, to improve their efforts against disease. Experts say that the funding pledged is not sufficient for preventing problems and will likely be used to deal with crises rather than the more cost-effective method of catching outbreaks early and

preventing the spread of an epidemic.

"Brief Report: Rifampin-Resistant Tuberculosis in a Patient Receiving Rifabutin Prophylaxis"
New England Journal of Medicine (06/13/96) Vol. 334, No. 24; P. 1573; Bishai, William R.; Graham, Neil M.H.; Harrington, Susan; et al.

Drug-resistant tuberculosis (TB) is a growing problem in the United States, and resistance to rifampin, a popular TB prophylactic drug for HIV-infected patients, is especially threatening. Nine percent of TB cases in New York City in 1991 were rifampin-resistant, up from less than 1 percent in 1979. Furthermore, prophylactic use of rifabutin, introduced in 1993, may induce rifampin-resistant TB. Dr. William R. Bishai, of Johns Hopkins University, and colleagues present the case of a 35-year-old man with HIV who was hospitalized and treated for TB. He was cleared of M. tuberculosis after six months of treatment, including treatment with rifampin. The patient then began seeing a private doctor and began taking rifabutin as prophylaxis against TB. Two months later, the patient developed symptoms of TB and died; a strain of M. tuberculosis resistant to rifampin and rifabutin was found to be the cause. The man's first and second episodes of TB were caused by strains that were identical except that the second one was resistant to rifabutin and rifampin. The researchers conclude that it is important to screen all patients for active TB before starting rifabutin prophylaxis, as is recommended by the Public Health Service.

"Blood Samples Called Safe for Mail Handlers"
Federal Times (06/10/96) Vol. 32, No. 18; P. 10; Bridger, Chet

Following the recent approval of the country's first mail-in HIV test kit comes approval for postal workers to carry the blood samples. Both the U.S. Postal Service and Johnson & Johnson, the maker of the Confide HIV test, said carrying the packages was not a health risk for postal workers. The Confide sample to be mailed consists of three dried blood spots on a card. The card will be sealed in a plastic container, sealed in a cardboard container, sealed inside a shipping box. The boxes will be handled manually and will be labeled as clinical specimens, carrying a green border that identifies them as HIV tests. All packages will be sent to Laboratory Corporation of America near Bridgewater, N.J. Johnson & Johnson says the kits could account for more than 5 million pieces of mail next year. The test kit will be available in Texas and Florida this summer and will be offered nationwide in 1997.

"HIV/AIDS Clinical Trials Videotape Package Now Available"
AIDS Clinical Trials Information Service (ACTIS) (06/18/96)

The new HIV/AIDS Clinical Trials: Knowing Your Options videotape package is now available from the AIDS Clinical Trials Information Service (ACTIS). ACTIS is a national information and referral service that provides the latest details on federally and privately sponsored clinical trials for experimental drugs and other HIV-related therapies for adults and children. The HIV/AIDS Clinical

Trials: Knowing Your Options package includes a VHS videotape, a discussion leader's guide, and a brochure. The 19-minute videotape clearly explains what HIV/AIDS clinical trials are and presents a simple "Learn, Consider, and Choose" approach for making personal decisions related to trials. The video features interviews with people who have participated in clinical trials as well as doctors and nurses who work in medical research programs. The HIV/AIDS Clinical Trials: Knowing Your Options package and additional copies of the brochure can be ordered from ACTIS (1-800-874-2572). There are nominal fees for the video package and extra brochures to cover shipping and handling costs. The videotape package costs $15 and extra brochures are 10> per copy. Discounts are available for bulk orders.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:19-JUN-1996 11:40:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I63B0HWT1C00010Z@PMDF.EOP.GOV> for levi_j@a1.eop.gov; Wed, 19 Jun 1996 11:37:10 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I63B3UBGI400007X@STORM.EOP.GOV> for levi_j@a1.eop.gov; Wed, 19 Jun 1996 11:39:50 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA18579; Wed, 19 Jun 1996 11:39:00 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 17:58:18.45

SUBJECT: Chavez meeting

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 09:56:41.09

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:24-JUN-1996 09:32:55.93

TEXT:
The HRSA interviews have been rescheduled for Tuesday, instead of July 5th -- so I won't be here for the Chavez meeting. Since I need to go to HCFA on Monday afternoon-- we should talk Monday morning about the SAMHSA issues.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 07:25:10.39

SUBJECT: RE: Background on Woolsey call

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:19-JUN-1996 12:46:44.14

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:19-JUN-1996 10:07:58.34

CC: Jennifer L. Klein (KLEIN_J) (OPD)
READ:19-JUN-1996 08:38:07.80

CC: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:24-JUN-1996 17:13:23.39

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:19-JUN-1996 09:08:13.39

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:19-JUN-1996 12:02:42.23

CC: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:19-JUN-1996 08:34:24.56

TEXT:
I think we can tell her everything from the memo: that the HCFA letter is going out within the week; that OPM has committed to putting in writing that medical foods should be covered -- and that they will be sending that to all their carriers.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUN-1996 07:25:41.33

SUBJECT:

TEXT:
I am in Rockville Wednesday morning -- I can be paged or reached after 1 p.m.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 12:01:56.47

SUBJECT: letterhead

TO: Remote Addressee (KSF@s-3.com@INET@EOPMRX)
READ:NOT READ

TEXT:
Would it be possible for you to fed ex to me a few sheets of the Advisory Council letterhead -- I need to get some stuff out for Scott that should be on letterhead -- thanks (unless there is a macro or something to do it from the computer -- but I doubt our software would know how).

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 13:54:20.54

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 10:24:22.15

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:21-JUN-1996 14:33:20.13

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:NOT READ

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:20-JUN-1996 13:49:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 06/20/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
June 20, 1996

****

"5 Research Teams Identify Key Step in HIV Infection"
"Lifeline: HIV and Birth"
"Bad Blood Left Her Life in Ruins"
"BioChem Shares Plummet"
"Lawsuits by Hemophiliacs to Result in Special Losses"
"Kiki Mason, a Writer on AIDS, Dies at 36"
"Spine-Tingling"
"Spread of Intestinal Infection Baffles Scientists"

"Viral Load Approved; Free Test Offered to All in U.S. With HIV"
****

"5 Research Teams Identify Key Step in HIV Infection"
Washington Post (06/20/96) P. A14; Brown, David

An essential receptor for HIV to infect the body's immune cells was simultaneously found by five different research teams. While the finding will not have an immediate impact on treating HIV infection, it will provide a new target for future drugs. The research was published this week in the journals Cell and Nature, and another paper will be published next week in Science. The finding, that a receptor called CKR5 must exist on the surface of immune system cells for HIV to infect them, adds to previous knowledge of HIV's infection process. Scientists had found another receptor, called CD4, that is necessary for the virus to infect a cell, but were seeking the other critical element. A co-receptor called fusin was identified earlier this year, but was found to only be necessary for a type of HIV found in the late stages of HIV infection. CKR5 appears to be needed for the type of virus that is transmitted between people and infects cells initially.

"Lifeline: HIV and Birth"
USA Today (06/20/96) P. 1D

Delivering a baby immediately after the mother's water breaks may be important to reduce the risk of transmitting HIV to the child, researchers report in today's New England Journal of Medicine. A baby born more than four hours after a woman's water breaks is twice as likely to be infected as one delivered sooner. Being exposed to the mother's body fluids may make the difference, researchers speculate. The study was conducted, however, before pregnant women and newborns were routinely treated with AZT, so shorter labors may not have an affect on women and babies treated with the drug, the researchers warn.

"Bad Blood Left Her Life in Ruins"
Philadelphia Inquirer (06/20/96) P. A1; Shaw, Donna

Judith Trullinger, who lost her only son to AIDS after he became infected with HIV through tainted blood products he used to treat his hemophilia, is now in severe debt, without support from government agencies. She would be eligible to receive at least $100,000 under a settlement being offered by four pharmaceutical companies, but the money could prove to be a disadvantage for several reasons. Trullinger, for example, would have to repay income taxes she owes, and the government could deny her potential benefits based on financial need. The settlement proposal could fail because of the benefits issue, since many of the HIV-positive hemophiliacs depend on public assistance. Lawyers for the hemophiliacs are trying to resolve the issue, possibly by including a provision that the government would not have access to the money from the settlement. Another solution may be for the government to compensate HIV-infected hemophiliacs through a special fund.

"BioChem Shares Plummet"
Toronto Globe and Mail (06/19/96) P. B1; Northfield, Stephen

BioChem Pharma saw its shares drop Tuesday over concerns that its AIDS drug 3TC would face competition from a drug being developed by Glaxo Wellcome. 3TC had won 35 percent of the North American market since it was introduced earlier this year, passing sales of AZT, Glaxo's older drug that had been the dominant AIDS treatment. An article in Monday's issue of Barron's reported that Glaxo is likely to release an AIDS drug to challenge 3TC in July. Some analysts said the situation is based on rumors and that the drug is actually an improvement of Glaxo's AZT and could be used in combination with 3TC.

"Lawsuits by Hemophiliacs to Result in Special Losses"
Wall Street Journal (06/20/96) P. B4

Japanese pharmaceutical company Green Cross has said that it will report at least 3 billion yen, or $27.8 million, in extraordinary losses for the year ending March 1997 resulting from lawsuits brought by HIV-infected hemophiliacs. The number of plaintiffs who are suing the company for supplying unheated blood products that potentially carried HIV has increased by 120 since May, raising the company's legal fees by 1.4 billion yen. More lawsuits this fiscal year could further increase the drug maker's losses.

"Kiki Mason, Writer on AIDS, Dies at 36"
New York Times (06/20/96) P. D21

Kiki Mason, an AIDS advocate and writer, died of the disease on Wednesday at the age of 36. Mason served as vice president of the board of the Community Research Initiative on AIDS, a nonprofit organization that explores new medical treatments, and wrote a column for Poz magazine about his own struggle with AIDS. He was active in the gay-rights movement in New York in the 1980s, and in 1993 founded a group that advocated increased treatment for people with Kaposi's sarcoma, an AIDS-related cancer.

"Spine-Tingling"
Washington Times (06/20/96) P. A5

ACT UP, the AIDS Coalition to Unleash Power, is planning a protest today at Democratic Party headquarters in Philadelphia. The demonstration is designed to make sure President Clinton does not allow the state to waive welfare and health care. The group claimed that it would give Clinton "a spine so that he can resist his urges to attempt to please ultra-conservatives seeking to tear down key safeguards for people with HIV/AIDS and poor people."

"Spread of Intestinal Infection Baffles Scientists"
New York Times (06/20/96) P. A14; Altman, Lawrence K.

Since early May, a few hundred cases of intestinal infection caused by an exotic microbe have been reported in Canada and the United States. Health officials are perplexed by the outbreak of cyclospora, which causes cramping, abdominal pain, diarrhea,

nausea, fever, and fatigue. The microbe has appeared in several areas, including New York City, New Jersey, Houston, Florida, Boston, and Toronto. Strawberries are one suspected carrier, although some people became infected without eating them. The Ontario health department has warned people to wash strawberries imported from the United States, and has recommended that people with compromised immune systems, including AIDS and cancer patients, not eat the berries.

"Viral Load Approved; Free Test Offered to All in U.S. With HIV"
AIDS Treatment News (06/07/96) No. 248; P. 1; James, John S.

On June 3, when the Food and Drug Administration approved the first viral load test for clinical use in the United States, the manufacturer, Hoffmann-La Roche, said each HIV-infected person in the country would be eligible for two free baseline tests. It is recommended that two tests be performed, and that a patient not be tested within a month of an acute illness or immunization. The new test, called the Amplicor HIV-1 Monitor, is based on polymerase chain reaction, one of three models for measuring viral load. Although viral load testing has been available to U.S. doctors for two years, the approval of Roche's test makes such testing more reliable. A commentary accompanying the article, discusses the controversy over approved uses of the test. At issue is whether the test would be recommended for prognosis only or also for monitoring a patient's progress over time. A statement from the FDA on clinical use of the test says that while the value in monitoring viral load has not been firmly established, it is now being evaluated.

========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========
ATT CREATION TIME/DATE:20-JUN-1996 13:50:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I64TUXPTE8000W93@PMDF.EOP.GOV> for levi_j@a1.eop.gov; Thu, 20 Jun 1996 13:47:52 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I64TY9NBKO00007Z@STORM.EOP.GOV> for levi_j@a1.eop.gov; Thu, 20 Jun 1996 13:50:33 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id NAA22621; Thu, 20 Jun 1996 13:49:46 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 2 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:20-JUN-1996 18:50:48.74

SUBJECT: It's 7:00. Need you're weekly.

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:NOT READ

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-JUN-1996 10:36:10.85

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:NOT READ

TO: Dennis Burke (BURKE_D) (OPD)
READ:20-JUN-1996 18:50:47.16

TO: Diane Regas (REGAS_D) (OPD)
READ:20-JUN-1996 22:45:38.25

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:NOT READ

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 10:03:35.36

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-JUN-1996 08:45:26.34

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:20-JUN-1996 18:51:07.65

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-JUN-1996 20:08:15.13

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:20-JUN-1996 19:00:21.70

TO: Michael T. Schmidt (SCHMIDT_MT)
READ:NOT READ

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:20-JUN-1996 18:53:34.24

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:21-JUN-1996 09:10:20.28

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:20-JUN-1996 18:54:02.21

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 13:41:40.89

SUBJECT: fyi

TO: Carmena Parris (PARRIS_C) (OPD)
READ:21-JUN-1996 07:49:18.59

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:20-JUN-1996 13:37:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jill Pizzuto

ATT SUBJECT: Staff Meeting next week

ATT TO: Lyndell Hogan (HOGAN_L)

ATT TO: Jeremy D. Benami (BENAMI_J)

ATT TO: Christopher C. Jennings (JENNINGS_C)

ATT TO: Jennifer L. Klein (KLEIN_J)

ATT TO: Cathy R. Mays (MAYS_C)

ATT TO: Denise Ricketson (RICKETSON_D)

ATT TO: Michael T. Schmidt (SCHMIDT_MT)

ATT TO: Stephen C. Warnath (WARNATH_S)

ATT TO: Paul J. Weinstein, Jr (WEINSTEIN_P)

ATT TO: Diana M. Fortuna (FORTUNA_D)

ATT TO: Carol H. Rasco (RASCO_C)

ATT TO: Janet B. Abrams (ABRAMS_J)

ATT TO: Dorothy L. Karayannis (KARAYANNIS_D)

ATT TO: Patsy Fleming (FLEMING_P)

ATT TO: Jeffrey Levi (LEVI_J)

ATT TO: Elizabeth E. Drye (DRYE_E)

ATT TO: Deborah L. Fine (FINE_D)

ATT TO: Dennis Burke (BURKE_D)

ATT TO: Diane Regas (REGAS_D)

ATT TO: Jill Pizzuto (PIZZUTO_J)

ATT TO: Julie E. Demeo (DEMEO_J)

ATT TO: Molly Brostrom (BROSTROM_M)

ATT TO: FAX (9-720-4732,Elworth, Larry) (TLXA1MAIL_\F:9-720-4732\C:Elworth, Larry\\ )

TEXT:

fyi to all:
Because both Carol and Jeremy will be at the Nashville conference on Monday, we will hold the Staff Meeting on TUESDAY, June 25th.
Regarding Monday, Conference Code number is: 6543. Should anyone like to sit in on it, it'll still be held in Jeremy's office.
THANKS.
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 14:25:59.02

SUBJECT: conference call

TO: Carmena Parris (PARRIS_C) (OPD)
READ:21-JUN-1996 07:50:47.57

TEXT:
Can you set up another conference call (dial in number again) for Helen Gayle, Joe O'Neill and me to discuss the counseling and testing proposal I have e-mailed to them today...trying for Thursday or Friday of next week (6/27 or 6/28). Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 13:07:29.46

SUBJECT: weekly on i drive

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:20-JUN-1996 16:50:51.12

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 14:16:01.39

SUBJECT: Testing project

TO: Remote Addressee (hdg1@cpsod1.em.cdc.gov@INET)
READ:NOT READ

TO: Remote Addressee (JONEILL@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 09:58:04.04

TEXT:
PRINTER FONT 10_POINT_COURIER
Helene and Joe: The following is an attempt at summarizing our conversation last week. I hope it reflects where we are all going and that we can move forward with this quickly. I will ask Carmena to set up a conference call for us sometime late next week to discuss this and the "internal" process we need to undertake.
I am still thinking of this as a joint CAPS

-NMAC effort.
Thanks again to both of you for your time and creativity on this.
Jeff

PRINTER FONT 12_POINT_COURIER
DRAFT DRAFT DRAFT DRAFT

Dialogue on HIV Counseling and Testing

Background: Since it was first licensed, the role of the HIV antibody test has evolved over time -- as we have learned its value as a diagnostic tool, as the technology of testing has also changed, and, perhaps most importantly, as our capacity for medical intervention has improved. The structures, policies, and messages associated with counseling and testing have not always kept pace, resulting in a significant number --- some estimates are as high as one half -- of people with HIV not knowing their antibody status. This denies individuals with HIV the opportunity to consider early treatment options and represents a potential threat to the public health.
Objective: To provide a forum for discussion by key government, community, and scientific leaders of how the role of counseling and testing has evolved to create a foundation for a new consensus regarding the role of counseling and testing in our public health response to HIV. A formal consensus statement would not result; however it is hoped that the dialogue would result in creative new approaches that could be brought back to each of the sectors represented in the discussion.
Method: A roundtable discussion by approximately 25

-30 key players.
Presentations or commissioned papers would focus the discussion. These would provide essential background in at least the following areas:
o How are people currently accessing counseling and testing?
o What do we know about why people are not being tested?
o What new approaches for reaching different populations are being tested? (examples: GMHC model; HCFA model re 076; NAPWA's testing day; we would also need to find ones regarding special populations, integration into primary care, etc.)
o How are new technologies affecting this discussion? (home testing, rapid testing, etc.)
In light of what is learned from the above, key issues for discussion would be:
o Do we need a new message about counseling and testing? How does the message vary based on population targeted?
o Do we need to adapt how we do counseling and testing and where we do it?
o Are there related policies or issues that must be addressed to accomplish the goal of getting more people to know their serostatus? (This includes legal barriers, stigma associated with testing and being positive, etc.)
o What additional research is needed?
The discussion would need to be practical, focused, and realistic. For

example, we are not going to achieve universal health care coverage from this discussion -- we must focus on the reality of existing government resources and structures and how they can be adapted to address the evolution of the role of HIV testing.
Who: To work, this must be a small group (25

-30 people) who are
representative of the groups and entities that must be reached. We would need to include representatives of the Federal government (CDC, HRSA, HCFA, SAMHSA, NIH), state and local government, HIV community activists, scientists, and media/social marketing experts.
When: September

-November 1996. This should be a short process; no more than three meetings. Since no formal "statement" must emerge, it should not be a complicated process. We need to work on a short time frame in order to be responsive in our programs to the rapidly evolving science.

Withdrawal/Redaction Marker
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
004. email	From: Jeremy Benami, To: Many Recipients, Re: FYI - Silverman Bday (4 pages)	06/20/1996	Personal Misfile

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:20-JUN-1996 13:47:00.00

SUBJECT: CDC AIDS Daily Summary 06/20/96

TO: levi_j (levi_j@A1@CD) (WHO)
READ:20-JUN-1996 13:54:02.68

TEXT:

AIDS Daily Summary
June 20, 1996

****

****

"5 Research Teams Identify Key Step in HIV Infection"
Washington Post (06/20/96) P. A14; Brown, David

An essential receptor for HIV to infect the body's immune cells was simultaneously found by five different research teams. While the finding will not have an immediate impact on treating HIV infection, it will provide a new target for future drugs. The research was published this week in the journals Cell and Nature, and another paper will be published next week in Science. The finding, that a receptor called CKR5 must exist on the surface of immune system cells for HIV to infect them, adds to previous knowledge of HIV's infection process. Scientists had found another receptor, called CD4, that is necessary for the virus to infect a cell, but were seeking the other critical element. A co-receptor called fusin was identified earlier this year, but was found to only be necessary for a type of HIV found in the late stages of HIV infection. CKR5 appears to be needed for the

type of virus that is transmitted between people and infects cells initially.

"Lifeline: HIV and Birth"
USA Today (06/20/96) P. 1D

Delivering a baby immediately after the mother's water breaks may be important to reduce the risk of transmitting HIV to the child, researchers report in today's New England Journal of Medicine. A baby born more than four hours after a woman's water breaks is twice as likely to be infected as one delivered sooner. Being exposed to the mother's body fluids may make the difference, researchers speculate. The study was conducted, however, before pregnant women and newborns were routinely treated with AZT, so shorter labors may not have an affect on women and babies treated with the drug, the researchers warn.

"Bad Blood Left Her Life in Ruins"
Philadelphia Inquirer (06/20/96) P. A1; Shaw, Donna

Judith Trullinger, who lost her only son to AIDS after he became infected with HIV through tainted blood products he used to treat his hemophilia, is now in severe debt, without support from government agencies. She would be eligible to receive at least $100,000 under a settlement being offered by four pharmaceutical companies, but the money could prove to be a disadvantage for several reasons. Trullinger, for example, would have to repay income taxes she owes, and the government could deny her potential benefits based on financial need. The settlement proposal could fail because of the benefits issue, since many of the HIV-positive hemophiliacs depend on public assistance. Lawyers for the hemophiliacs are trying to resolve the issue, possibly by including a provision that the government would not have access to the money from the settlement. Another solution may be for the government to compensate HIV-infected hemophiliacs through a special fund.

"BioChem Shares Plummet"
Toronto Globe and Mail (06/19/96) P. B1; Northfield, Stephen

BioChem Pharma saw its shares drop Tuesday over concerns that its AIDS drug 3TC would face competition from a drug being developed by Glaxo Wellcome. 3TC had won 35 percent of the North American market since it was introduced earlier this year, passing sales of AZT, Glaxo's older drug that had been the dominant AIDS treatment. An article in Monday's issue of Barron's reported that Glaxo is likely to release an AIDS drug to challenge 3TC in July. Some analysts said the situation is based on rumors and that the drug is actually an improvement of Glaxo's AZT and could be used in combination with 3TC.

"Lawsuits by Hemophiliacs to Result in Special Losses"
Wall Street Journal (06/20/96) P. B4

Japanese pharmaceutical company Green Cross has said that it will report at least 3 billion yen, or $27.8 million, in extraordinary losses for the year ending March 1997 resulting from lawsuits brought by HIV-infected hemophiliacs. The number

of plaintiffs who are suing the company for supplying unheated blood products that potentially carried HIV has increased by 120 since May, raising the company's legal fees by 1.4 billion yen. More lawsuits this fiscal year could further increase the drug maker's losses.

"Kiki Mason, Writer on AIDS, Dies at 36"
New York Times (06/20/96) P. D21

Kiki Mason, an AIDS advocate and writer, died of the disease on Wednesday at the age of 36. Mason served as vice president of the board of the Community Research Initiative on AIDS, a nonprofit organization that explores new medical treatments, and wrote a column for Poz magazine about his own struggle with AIDS. He was active in the gay-rights movement in New York in the 1980s, and in 1993 founded a group that advocated increased treatment for people with Kaposi's sarcoma, an AIDS-related cancer.

"Spine-Tingling"
Washington Times (06/20/96) P. A5

ACT UP, the AIDS Coalition to Unleash Power, is planning a protest today at Democratic Party headquarters in Philadelphia. The demonstration is designed to make sure President Clinton does not allow the state to waive welfare and health care. The group claimed that it would give Clinton "a spine so that he can resist his urges to attempt to please ultra-conservatives seeking to tear down key safeguards for people with HIV/AIDS and poor people."

"Spread of Intestinal Infection Baffles Scientists"
New York Times (06/20/96) P. A14; Altman, Lawrence K.

Since early May, a few hundred cases of intestinal infection caused by an exotic microbe have been reported in Canada and the United States. Health officials are perplexed by the outbreak of cyclospora, which causes cramping, abdominal pain, diarrhea, nausea, fever, and fatigue. The microbe has appeared in several areas, including New York City, New Jersey, Houston, Florida, Boston, and Toronto. Strawberries are one suspected carrier, although some people became infected without eating them. The Ontario health department has warned people to wash strawberries imported from the United States, and has recommended that people with compromised immune systems, including AIDS and cancer patients, not eat the berries.

"Viral Load Approved; Free Test Offered to All in U.S. With HIV"
AIDS Treatment News (06/07/96) No. 248; P. 1; James, John S.

On June 3, when the Food and Drug Administration approved the first viral load test for clinical use in the United States, the manufacturer, Hoffmann-La Roche, said each HIV-infected person in the country would be eligible for two free baseline tests. It is recommended that two tests be performed, and that a patient not be tested within a month of an acute illness or immunization. The new test, called the Amplicor HIV-1 Monitor, is based on polymerase chain reaction, one of three models for

measuring viral load. Although viral load testing has been available to U.S. doctors for two years, the approval of Roche's test makes such testing more reliable. A commentary accompanying the article, discusses the controversy over approved uses of the test. At issue is whether the test would be recommended for prognosis only or also for monitoring a patient's progress over time. A statement from the FDA on clinical use of the test says that while the value in monitoring viral load has not been firmly established, it is now being evaluated.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:20-JUN-1996 13:50:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I64TUXPTE8000W93@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 20 Jun 1996 13:47:52 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I64TY9NBKO00007Z@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Thu, 20 Jun 1996 13:50:33 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id NAA22621; Thu,
20 Jun 1996 13:49:46 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 13:16:32.88

SUBJECT: Interview questions

TO: Remote Addressee (DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
PRINTER FONT 12_POINT_ROMAN
Dora -- a few questions for your consideration:
During this second five year period of the Ryan White CARE Act -- what do you see as the new challenges facing HIV care and services and how must HRSA's programs adapt to meet these new challenges?
How would you bring HRSA staff and constituents to understand and embrace this perspective?
As you think about this position, what three things would you most like to accomplish during your tenure over the next year? the next five years?
How would you describe your management style?
How would you describe your decision

-making style?
Jeff

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:20-JUN-1996 18:51:42.03

SUBJECT: I mean your weekly, thanks.

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:20-JUN-1996 22:39:45.86

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-JUN-1996 10:36:12.98

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:03:04.35

TO: Dennis Burke (BURKE_D) (OPD)
READ:20-JUN-1996 19:36:48.19

TO: Diane Regas (REGAS_D) (OPD)
READ:20-JUN-1996 22:45:50.14

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:NOT READ

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 10:03:48.61

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:20-JUN-1996 19:05:02.82

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:20-JUN-1996 18:53:10.60

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-JUN-1996 20:08:31.91

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:20-JUN-1996 19:00:34.84

TO: Michael T. Schmidt (SCHMIDT_MT)
READ:NOT READ

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:20-JUN-1996 18:53:39.03

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:21-JUN-1996 09:10:29.54

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:20-JUN-1996 18:55:11.87

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:20-JUN-1996 13:40:35.20

SUBJECT: Staff Meeting next week

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:20-JUN-1996 14:59:17.58

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:20-JUN-1996 13:47:39.24

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:24-JUN-1996 20:34:53.57

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:20-JUN-1996 14:34:35.59

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:20-JUN-1996 13:44:35.93

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:20-JUN-1996 14:16:38.89

TO: Michael T. Schmidt (SCHMIDT_MT)
READ:NOT READ

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:20-JUN-1996 13:45:01.36

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:20-JUN-1996 14:25:49.98

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:20-JUN-1996 13:43:03.93

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:20-JUN-1996 15:41:48.72

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:20-JUN-1996 14:10:19.53

TO: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)
READ:20-JUN-1996 14:26:54.71

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 09:57:32.19

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-JUN-1996 13:41:16.19

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:20-JUN-1996 16:53:29.56

TO: Deborah L. Fine (FINE_D) (OPD)
READ:20-JUN-1996 13:41:23.71

TO: Dennis Burke (BURKE_D) (OPD)
READ:20-JUN-1996 13:54:01.82

TO: Diane Regas (REGAS_D) (OPD)
READ:20-JUN-1996 14:10:01.50

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:20-JUN-1996 13:41:07.36

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:25-JUN-1996 11:01:47.62

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 08:52:00.38

TO: FAX (9-720-4732,Elworth, Larry) (TLXA1MAIL_\F:9-720-4732\C:Elworth, Larry\\ )
READ:NOT READ

TEXT:

fyi to all:
Because both Carol and Jeremy will be at the Nashville conference on Monday, we will hold the Staff Meeting on TUESDAY, June 25th.
Regarding Monday, Conference Code number is: 6543. Should anyone like to sit in on it, it'll still be held in Jeremy's office.
THANKS.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 08:54:27.52

SUBJECT: RE: interviews for Dir, Bureau of Hlth Res Dev

TO: DORA OBER (DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
what time will the committee need to be at Parklawn next week?
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:20-JUN-1996 11:16:30.09

SUBJECT: The pilot

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-JUN-1996 11:26:34.36

TEXT:
Jeff -- I have information on the HIV+ pilot. Let's discuss when you get a chance.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:20-JUN-1996 16:53:08.54

SUBJECT: Weekly Reminder Your Weekly Is Due COB Today Thanks.

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:NOT READ

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:NOT READ

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 08:52:52.11

TO: Dennis Burke (BURKE_D) (OPD)
READ:20-JUN-1996 16:55:19.71

TO: Diane Regas (REGAS_D) (OPD)
READ:20-JUN-1996 17:09:23.85

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:NOT READ

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:20-JUN-1996 18:01:00.13

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-JUN-1996 08:45:04.45

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:20-JUN-1996 18:31:40.05

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:20-JUN-1996 16:53:23.78

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:20-JUN-1996 17:32:57.60

TO: Michael T. Schmidt (SCHMIDT_MT)
READ:NOT READ

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:20-JUN-1996 17:09:34.39

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:21-JUN-1996 09:10:12.77

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:20-JUN-1996 17:50:39.08

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 17:35:19.38

SUBJECT: Additions

TO: Daniel P. Collins (COLLINS_D) (WHO)
READ:20-JUN-1996 17:35:44.83

TEXT:
I think it's good to have the general stuff, but it might also help to have some language specific to prevention activities. Here's a sampler:
The President has made prevention of the spread of HIV among young people a top priority. He requested that the Office of National AIDS Policy prepare a special report for him on Youth and HIV/AIDS. The report was highlighted in a recent Ann Landers column. He has requested increased funding for prevention activities at the CDC; these funds would be sued to support programs that reach youth who are at risk. In 1994, the CDC launched the Prevention Marketing Initiative, which focuses AIDS prevention activity on young adults (18-25). PMI features an award-winning public service announcement campaign.

....or some version of this.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:20-JUN-1996 17:42:22.68

SUBJECT: SSA mailing

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:02:45.35

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 10:04:05.17

TEXT:
Remember the mailing SSA was going to send out to the groups explaining the recertification issue? Guess when the AIDS groups got theirs -- yesterday! Real helpful in getting the word out about the 10 day period -- since so many were well into (or beyond) it. Oh well...

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 11:09:00.00

SUBJECT: CDC AIDS Daily Summary 06/21/96

TO: levi_j (levi_j@A1@CD) (WHO)
READ:21-JUN-1996 11:37:17.17

TEXT:

AIDS Daily Summary
June 21, 1996

****

****

"Slovenian Man Said to Get HIV From Human Bite"
Baltimore Sun (06/21/96) P. 13A

In the first such documented case, a Slovenian man became infected with HIV after his neighbor bit him, doctors said Thursday. Ludvik Vidmar and colleagues at the Department of Infectious Diseases in Ljubljana report that the incident occurred when a 47-year-old HIV-infected homosexual sought help from his neighbor when he had a seizure. The 53-year-old neighbor, who did not know the man had HIV, became infected when he put his hand in the man's mouth to keep him from swallowing his tongue.

"Protesters Block Entrance to Rally"
Washington Times (06/21/96) P. C8

Jeff Getty, who received a baboon bone marrow transplant last year as an experimental treatment for AIDS, was arrested with eight other demonstrators for blocking traffic at an animal rights rally on Thursday. About 25 demonstrators from the AIDS activist group ACT-UP had been blocking the entrance to the USAir Arena, but they were all released after paying a $15 fine. The AIDS activists, who argued that animal research is critical for medical progress, were protesting the animal rights groups' annual attempts to lobby Congress for stronger laws protecting animals used in scientific research.

"Agouron Pharmaceuticals, Roche Sign Agreement to Develop Cancer Drugs"
Wall Street Journal (06/21/96) P. B7; Rundle, Rhonda L.

Agouron Pharmaceuticals said that it had entered a deal with Roche Holding in which Roche would pay Agouron between $150 million and $250 million over the next several years in exchange for a share of profits from anticancer drugs developed by Agouron. The two drugs covered in the pact, Thymitaq and AG3340, have combined sales potential of more than $500 million, said Jim McCamant, editor of the Medical Technology Stock Newsletter. McCamant said he was surprised that Roche was selected over Bristol-Myers Squibb, the world leader in cancer drugs and a developer of AIDS drugs. Agouron is pushing its own AIDS drug through human trials and is testing it in combination with a Bristol-Myers drug.

"Baltimorean Lives With HIV, Strives to Save Others From It"
Baltimore Sun (06/21/96) P. 1E; Thompson, M. Dion

Laurie Purdy, a 31-year-old woman from Baltimore, Md., said she surprises people when she shows up to speak about AIDS. She has been HIV-positive for six years, and for the past four years she has spread the message of HIV awareness to high school and college students and professional and amateur athletes. Tonight she will be featured with five other HIV-positive women on Lifetime television's "Late Date with Sari." The show, part of the fourth annual "Day of Compassion" effort to increase AIDS awareness, airs from 11 p.m. to midnight. The women discuss their experiences regarding their HIV diagnosis, discrimination, and the virus has changed their lives. They also stress the need for education.

"Key Molecule That Lets HIV Enter Cells Found"
Los Angeles Times (06/20/96) P. A1; Maugh, Thomas H. II

Researchers have identified a co-factor essential to HIV's ability to invade the body, opening new avenues for treatment and helping to explain why some individuals are more resistant to the virus. The co-factor, CKR5, seems to be more important than fusin, a co-factor identified last month, because it plays a part in the majority of HIV infections. Researchers discovered last year that certain chemicals called chemokines could block HIV's entry into the human white blood cells. This led to the search

for the chemokine receptors, one of which is CKR5. Researchers believe the different chemokine receptors may be specific to the various strains of HIV. CKR5 is thought to be the receptor for the kind of HIV that is most prevalent in the United States. Increasing a person's level of the chemical could help protect them from an HIV infection, or drugs could be designed to bind with the chemical, possibly preventing the virus' entry.

"South Carolina Will Permit Anonymous HIV Home Testing"
Reuters (06/20/96)

The governor of South Carolina has signed a law to allow the anonymous use of a home HIV-antibody test, bypassing the state policy that all positive HIV tests be reported. Besides South Carolina, 29 other states have a mandatory reporting law. Laboratories that perform the tests will still be required to report the results to the state but may not provide any identifying information.

"Court Rules That Lawsuit Against Baxter May Proceed"
United Press International (06/20/96)

A lawsuit filed by Zurich Insurance Co. against Baxter International may proceed, the Illinois Supreme Court ruled on Thursday. The case involves a Baxter drug that allegedly transmitted HIV to more than 8,000 hemophiliacs in the late 1970s and early 1980s. Zurich Insurance, which provided coverage for the drug maker, says it should not be responsible for covering Baxter's costs for defending, or settling, claims made by the hemophiliacs and their families who have sued the firm. The cost of settling claims in the case has been estimated to be about $128 million for Baxter.

"Immunosuppression: Major Predictor of Mortality in AIDS Patients With TB"
Reuters (06/20/96)

While HIV-infected patients who are co-infected with tuberculosis (TB) respond well to antituberculosis therapy, their overall survival is poor, researchers at Case Western Reserve University report. Survival seems to be determined largely by the degree of immunosuppression, resulting from either HIV or the impact of TB on HIV, Christopher Whalen and colleagues reported. The results are based on data from 191 HIV-positive adults treated at a TB treatment center in Kampala, Uganda. During the six-month follow-up, 43 percent of the patients died. Whalen said that preventing active disease and aggressively treating HIV infection during TB treatment may improve survival for HIV-infected patients with TB.

"Perinatal Intervention Trial in Africa: Effect of a Birth Canal Cleansing Intervention to Prevent HIV Transmission"
Lancet (06/15/96) Vol. 347, No. 9016, P. 1647; Biggar, Robert J.; Miotti, Paolo G.; Taha, Taha E.; et al.

The prevalence of HIV infection in African women and the rate of transmission from mother to infant requires a safe, low-cost mode of HIV transmission prevention. Treating pregnant

women and newborns with zidovudine can reduce the rate of transmission, but drug therapy is impractical in most of the world. Many experts believe the virus is transmitted during delivery, through birth canal exposure. Antiseptic cleansing of the birth canal was considered as a method to reduce transmission. The National Cancer Institute's Robert J. Biggar and other researchers conducted a clinical trial to determine the safety and efficacy of this method. The trial, held at Queen Elizabeth Central Hospital in Malawi, involved 3,327 infants of mothers who did not receive the intervention and 3,637 who did. The researchers report that, while the intervention had no adverse affect, it also had no significant impact on HIV infection rates. They conclude that if birth canal exposure is a risk factor, other methods for reducing risk should be tested.

"Catalog Targets AIDS-Sensitive Consumers"
DM News (06/10/96) Vol. 18, No. 22; P. 4; Emerson, Jim

The National Catalog Foundation (NCF) is using mailing lists provided by nonprofit groups to reach potential customers for its National AIDS Awareness Catalog. In return, the groups receive a portion of the sales generated by the catalog. The products include clothing, books, and general merchandise with and without rainbows, the symbol of gay unity, and red ribbons, the symbol of support of AIDS research. NCF President Jeffrey Zeidman says the products are attractive to customers because the proceeds benefit AIDS organizations. The catalog, issued three times a year, is two years old, and Zeidman plans to more than double circulation to at least 750,000. Over the last two years, about $60,000 was donated to AIDS organizations, including the Research Initiative on AIDS and the Gay Men's Health Crisis.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 11:11:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
 by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I662MCDZR4001OPM@PMDF.EOP.GOV> for
 levi_j@a1.eop.gov; Fri, 21 Jun 1996 11:09:02 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
 by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I662PMXNXU00007Z@STORM.EOP.GOV> for
 levi_j@a1.eop.gov; Fri, 21 Jun 1996 11:11:42 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA15515; Fri,
 21 Jun 1996 11:10:53 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jennifer L. Klein (KLEIN_J) (OPD)

CREATION DATE/TIME:21-JUN-1996 19:52:16.94

SUBJECT: Memo on Protease Inhibitors

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUN-1996 16:55:19.43

TEXT:
looks great to me.
See you when I get back from vacation!

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 14:16:00.00

SUBJECT: New Protocol Records 06/21/96 (3 of 3)

TO: levi_j (levi_j@A1@CD) (WHO)
READ:24-JUN-1996 07:47:50.50

TEXT:
New Protocol Records 06/21/96
Part 3 of 3

****

PROTOCOL NUMBER: NIAID VEU 022A.

TITLE: A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers.

PHASE: Phase I.

DISEASE STATUS:
Volunteers have the following conditions: 1. Normal history and physical exam. 2. Negative ELISA and Western blot for HIV within 8 weeks prior to immunization. 3. CD4 count >= 400 cells/mm3. 4. Normal urine dipstick with esterase and nitrite.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:
Volunteers must have:
1. Normal history and physical exam.
2. Negative ELISA and Western blot for HIV.
3. CD4 count >= 400 cells/mm3.
4. Normal urine dipstick with esterase and nitrite.
NOTE: No more than 10 percent of volunteers in each stratum may be over age 50.

AGE: 18 Years - 60 Years.
SEX: M. F.

REPRODUCTIVE SPECIFICATION:
Not pregnant. Negative pregnancy test. Not breast-feeding. Abstinence or effective method of birth control / contraception including oral contraceptives during the study.

RISK BEHAVIOR:
Allowed for volunteers stratified to the higher risk stratum:

High risk behavior for HIV infection, such as
- injection drug use within the past 12 months.
- higher or intermediate risk sexual behavior.

LABORATORY VALUES AT ENTRY

HEMATOCRIT: >= 34 percent. (women); >= 38 percent (men).
PLATELET COUNT: 150000 - 550000 platelets/mm3.
CD4 (T4 CELL) COUNT: >= 400 cells/mm3. (400 - 500 - 600 - 700 - 800 - plus).
SGPT (ALT): <= 1.5 x ULN. (ULN = upper limit of normal).
CREATININE: <= 1.6 mg/dl.
OTHER LABORATORY VALUES: WBC >= 3500 cells/mm3 with normal differential. Total lymphoycytes >= 800 cells/mm3.

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:
Subjects with the following prior conditions are excluded:
1. History of immunodeficiency, chronic illness, automimmune disease, or use of immunosuppressive medications.
2. History of anaphylaxis or other serious adverse reactions to vaccines.
3. Prior immunization against rabies.
4. History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g., Steven-Johnson syndrome, bronchospasm, or hypotension).
5. Prior psychiatric condition (such as history of suicide attempts or past psychosis) that precludes compliance.
6. History of cancer unless there has been surgical excision that is considered to have achieved cure.

AGE: 01 Days - 17 Years. 61 Years - 99 Years.

REPRODUCTIVE SPECIFICATION:
Pregnant. Positive pregnancy test. Breast-feeding. No abstinence or no agreement to use effective method of birth control / contraception during the study.

RISK BEHAVIOR:
For volunteers stratified to the lower risk stratum:
High risk behavior for HIV infection, such as
- injection drug use within the past 12 months.
- higher or intermediate risk sexual behavior.

PRIOR TREATMENT:
Excluded: Blood products or immunoglobulin within the past 6 months.

PRIOR MEDICATION:

Excluded:

1. Live attenuated vaccines within 60 days prior to study entry.
NOTE: Medically indicated killed or subunit vaccines (e.g., influenza, pneumococcal) do not exclude if administered at least 2 weeks from HIV immunizations.
2. Experimental agents within 30 days prior to study entry.
3. Prior HIV vaccines.
4. Prior rabies immunization.

CO-EXISTING CONDITIONS OR DISEASES:

Subjects with the following symptoms or conditions are excluded:

1. Positive hepatitis B surface antigen.
2. Medical or psychiatric condition (such as recent suicidal ideation or present psychosis) that precludes compliance.
3. Occupational responsibilities that preclude compliance.
4. Active syphilis. NOTE: Subjects with serology documented to be a false positive or due to a remote (> 6 months) treated infection are eligible.
5. Active tuberculosis. NOTE: Subjects with a positive PPD and a normal chest x-ray showing no evidence of TB and not requiring isoniazid therapy are eligible.
6. Allergy to egg products or neomycin.
7. Occupational exposure to birds.

AVAILABILITY:

Unavailable for 24 months of follow-up.

GENERIC DRUG NAME

Drug 1: ALVAC-HIV MN120TMG (vCP205). Vaccine.
Drug 2: rgp120/HIV-1SF2. Vaccine.
Drug 3: ALVAC-RG rabies glycoprotein (vCP65). Vaccine.

DRUG COMPANIES

Drug 1: Connaught Laboratories Incorporated / Pasteur Merieux
Route 611 / PO Box 187
Swiftwater, PA 18370
Contact: Ken Guito (717) 839-4212.

Drug 2: BIOCINE Company
4560 Horton Street
Emeryville, CA 94608-2916
Contact: Dr Anne-Marie Duliege (510) 601-2715.

Drug 3: Connaught Laboratories Incorporated / Pasteur Merieux
Route 611 / PO Box 187
Swiftwater, PA 18370
Contact: Ken Guito (717) 839-4212.

END POINT

Immunogenicity, safety.

PARTICIPATING UNITS

0000003328:
University of Alabama at Birmingham
908 20th Street South / CCB 178 / AVEU Clinic
Birmingham, AL 35294-2050
Contact: James Raper (205) 975-2840
OPEN 960612 ACTU: 6009.

0000001429:
St Louis University School of Medicine
1402 South Grand Boulevard
St Louis, MO 63104
Contact: Dr Robert B Belshe (314) 577-8648
OPEN 960612 ACTU: 6007.

0000002195:
University of Washington / Pacific Medical Center
1200 12th Avenue South / Room 9301
Seattle, WA 98144
Contact: David Berger (206) 621-4179
OPEN 960612 ACTU: 6008.

****

DRUG RECORD

Accession Number:
DRG-0247.
Generic Name:
HIV-1 Immunogen (FDA 092).
Protocol Number(s):
Open FDA 092
Alias/Trade Name:
Remune (Immune Response Corporation June 1996). Salk Immunogen (Immune Response Corporation June 1996). Salk HIV vaccine (Immune Response Corporation June 1996).
Drug Company(ies):
Immune Response Corporation
5935 Darwin Court
Carlsbad, CA 92008
Contact: Trial Information (800) 684-8624.
Therapeutic Classification:
Vaccine (FDA 092).
Drug Description:

gp120-depleted HIV-1 derived from Zairian strain HZ-321 that is propagated in HUT-78 cells, inactivated in beta-propriolactone and irradiation, and emulsified in mineral oil (Incomplete Freund's Adjuvant).
(Immune Response Corporation June 1996)

Pharmacology:
MODE OF ACTION: May slow replication of HIV-1 by stimulating the immune system to recognize HIV proteins and destroy cells infected with the virus. Theoretically, the use of inactivated virus could stimulate broader immune responses that are capable of suppressing more diverse strains of HIV than vaccines based on subunits of the virus.
(Immune Response Corporation June 1996)

Drug Interactions:
May complement action of antiretroviral drugs against infection.
(Immune Response Corporation June 1996)

Contraindications:
Contraindicated in pregnant or nursing women.
(FDA 092)

Mode of Delivery:
Intramuscular. (FDA 092)

AIDS-Related Uses:
HIV infection. (FDA 092)

Bibliographic References:
Slade HB, Jensen F, Trauger R, Ferre F, Tipping D, Salk J. Effect of Salk HIV immunogen in incomplete Freund's adjuvant on HIV-viral burden--report on RG 83894-103. Int Conf AIDS. 1993 Jun 6-11;9(1):71 (abstract no. WS-B28-1).

Turner JL, Slade HB, Trauger RJ, Ferre F, Jensen FC, Carlo DJ, Salk JE. Double-blind, placebo-controlled dose ranging study of Salk Immunogen in incomplete Freund's adjuvant in asymptomatic patient with early human immunodeficiency virus infection. Int Conf AIDS. 1992 Jul 19-24;8(2):B94 (abstract no. PoB 3043).

****

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 14:19:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0116695M9BMO001QAR@PMDF.EOP.GOV> for levi_j@a1.eop.gov; Fri, 21 Jun 1996 14:16:23 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0116698TEAE200007Z@STORM.EOP.GOV> for levi_j@a1.eop.gov; Fri, 21 Jun 1996 14:18:57 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id OAA01280; Fri, 21 Jun 1996 14:18:12 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com

Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-JUN-1996 11:39:55.11

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 10:27:22.18

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:21-JUN-1996 14:26:15.17

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:21-JUN-1996 12:28:32.30

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 11:10:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 06/21/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
June 21, 1996

****

"Slovenian Man Said to Get HIV From Human Bite"
"Protesters Block Entrance to Rally"
"Agouron Pharmaceuticals, Roche Sign Agreement to Develop Cancer Drugs"
"Baltimorean Lives With HIV, Strives to Save Others From It"
"Key Molecule That Lets HIV Enter Cells Found"
"South Carolina Will Permit Anonymous HIV Home Testing"
"Court Rules That Lawsuit Against Baxter May Proceed"

"Immunosuppression: Major Predictor of Mortality in AIDS Patients With TB"
"Perinatal Intervention Trial in Africa: Effect of a Birth Canal Cleansing Intervention to Prevent HIV Transmission"
"Catalog Targets AIDS-Sensitive Consumers"
****

"Slovenian Man Said to Get HIV From Human Bite"
Baltimore Sun (06/21/96) P. 13A

In the first such documented case, a Slovenian man became infected with HIV after his neighbor bit him, doctors said Thursday. Ludvik Vidmar and colleagues at the Department of Infectious Diseases in Ljubljana report that the incident occurred when a 47-year-old HIV-infected homosexual sought help from his neighbor when he had a seizure. The 53-year-old neighbor, who did not know the man had HIV, became infected when he put his hand in the man's mouth to keep him from swallowing his tongue.

"Protesters Block Entrance to Rally"
Washington Times (06/21/96) P. C8

Jeff Getty, who received a baboon bone marrow transplant last year as an experimental treatment for AIDS, was arrested with eight other demonstrators for blocking traffic at an animal rights rally on Thursday. About 25 demonstrators from the AIDS activist group ACT-UP had been blocking the entrance to the USAir Arena, but they were all released after paying a $15 fine. The AIDS activists, who argued that animal research is critical for medical progress, were protesting the animal rights groups' annual attempts to lobby Congress for stronger laws protecting animals used in scientific research.

"Agouron Pharmaceuticals, Roche Sign Agreement to Develop Cancer Drugs"
Wall Street Journal (06/21/96) P. B7; Rundle, Rhonda L.

Agouron Pharmaceuticals said that it had entered a deal with Roche Holding in which Roche would pay Agouron between $150 million and $250 million over the next several years in exchange for a share of profits from anticancer drugs developed by Agouron. The two drugs covered in the pact, Thymitaq and AG3340, have combined sales potential of more than $500 million, said Jim McCamant, editor of the Medical Technology Stock Newsletter. McCamant said he was surprised that Roche was selected over Bristol-Myers Squibb, the world leader in cancer drugs and a developer of AIDS drugs. Agouron is pushing its own AIDS drug through human trials and is testing it in combination with a Bristol-Myers drug.

"Baltimorean Lives With HIV, Strives to Save Others From It"
Baltimore Sun (06/21/96) P. 1E; Thompson, M. Dion

Laurie Purdy, a 31-year-old woman from Baltimore, Md., said she surprises people when she shows up to speak about AIDS. She has been HIV-positive for six years, and for the past four years she has spread the message of HIV awareness to high school and

college students and professional and amateur athletes. Tonight she will be featured with five other HIV-positive women on Lifetime television's "Late Date with Sari." The show, part of the fourth annual "Day of Compassion" effort to increase AIDS awareness, airs from 11 p.m. to midnight. The women discuss their experiences regarding their HIV diagnosis, discrimination, and the virus has changed their lives. They also stress the need for education.

"Key Molecule That Lets HIV Enter Cells Found"
Los Angeles Times (06/20/96) P. A1; Maugh, Thomas H. II

Researchers have identified a co-factor essential to HIV's ability to invade the body, opening new avenues for treatment and helping to explain why some individuals are more resistant to the virus. The co-factor, CKR5, seems to be more important than fusin, a co-factor identified last month, because it plays a part in the majority of HIV infections. Researchers discovered last year that certain chemicals called chemokines could block HIV's entry into the human white blood cells. This led to the search for the chemokine receptors, one of which is CKR5. Researchers believe the different chemokine receptors may be specific to the various strains of HIV. CKR5 is thought to be the receptor for the kind of HIV that is most prevalent in the United States. Increasing a person's level of the chemical could help protect them from an HIV infection, or drugs could be designed to bind with the chemical, possibly preventing the virus' entry.

"South Carolina Will Permit Anonymous HIV Home Testing"
Reuters (06/20/96)

The governor of South Carolina has signed a law to allow the anonymous use of a home HIV-antibody test, bypassing the state policy that all positive HIV tests be reported. Besides South Carolina, 29 other states have a mandatory reporting law. Laboratories that perform the tests will still be required to report the results to the state but may not provide any identifying information.

"Court Rules That Lawsuit Against Baxter May Proceed"
United Press International (06/20/96)

A lawsuit filed by Zurich Insurance Co. against Baxter International may proceed, the Illinois Supreme Court ruled on Thursday. The case involves a Baxter drug that allegedly transmitted HIV to more than 8,000 hemophiliacs in the late 1970s and early 1980s. Zurich Insurance, which provided coverage for the drug maker, says it should not be responsible for covering Baxter's costs for defending, or settling, claims made by the hemophiliacs and their families who have sued the firm. The cost of settling claims in the case has been estimated to be about $128 million for Baxter.

"Immunosuppression: Major Predictor of Mortality in AIDS Patients With TB"
Reuters (06/20/96)

While HIV-infected patients who are co-infected with

tuberculosis (TB) respond well to antituberculosis therapy, their overall survival is poor, researchers at Case Western Reserve University report. Survival seems to be determined largely by the degree of immunosuppression, resulting from either HIV or the impact of TB on HIV, Christopher Whalen and colleagues reported. The results are based on data from 191 HIV-positive adults treated at a TB treatment center in Kampala, Uganda. During the six-month follow-up, 43 percent of the patients died. Whalen said that preventing active disease and aggressively treating HIV infection during TB treatment may improve survival for HIV-infected patients with TB.

"Perinatal Intervention Trial in Africa: Effect of a Birth Canal Cleansing Intervention to Prevent HIV Transmission"
Lancet (06/15/96) Vol. 347, No. 9016, P. 1647; Biggar, Robert J.; Miotti, Paolo G.; Taha, Taha E.; et al.

The prevalence of HIV infection in African women and the rate of transmission from mother to infant requires a safe, low-cost mode of HIV transmission prevention. Treating pregnant women and newborns with zidovudine can reduce the rate of transmission, but drug therapy is impractical in most of the world. Many experts believe the virus is transmitted during delivery, through birth canal exposure. Antiseptic cleansing of the birth canal was considered as a method to reduce transmission. The National Cancer Institute's Robert J. Biggar and other researchers conducted a clinical trial to determine the safety and efficacy of this method. The trial, held at Queen Elizabeth Central Hospital in Malawi, involved 3,327 infants of mothers who did not receive the intervention and 3,637 who did. The researchers report that, while the intervention had no adverse affect, it also had no significant impact on HIV infection rates. They conclude that if birth canal exposure is a risk factor, other methods for reducing risk should be tested.

"Catalog Targets AIDS-Sensitive Consumers"
DM News (06/10/96) Vol. 18, No. 22; P. 4; Emerson, Jim

The National Catalog Foundation (NCF) is using mailing lists provided by nonprofit groups to reach potential customers for its National AIDS Awareness Catalog. In return, the groups receive a portion of the sales generated by the catalog. The products include clothing, books, and general merchandise with and without rainbows, the symbol of gay unity, and red ribbons, the symbol of support of AIDS research. NCF President Jeffrey Zeidman says the products are attractive to customers because the proceeds benefit AIDS organizations. The catalog, issued three times a year, is two years old, and Zeidman plans to more than double circulation to at least 750,000. Over the last two years, about $60,000 was donated to AIDS organizations, including the Research Initiative on AIDS and the Gay Men's Health Crisis.

========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========
ATT CREATION TIME/DATE:21-JUN-1996 11:11:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <011662MCDZR4001OPM@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 11:09:02 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <011662PMXNXU00007Z@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 11:11:42 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA15515; Fri,
21 Jun 1996 11:10:53 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 2 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Diana M. Fortuna (FORTUNA_D) (OPD)

CREATION DATE/TIME:21-JUN-1996 12:08:43.14

SUBJECT: hot ny issues

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUN-1996 16:48:02.46

TEXT:
I am reviewing the attached report from HHS, sent to Cabinet Affairs to review any "hot" issues in anticipation of the President's trip to NY. I saw the Ryan White item, and thought you should see it. My plan on the other items is to let Cabinet Affairs know of any cases where HHS's write-up doesn't capture the full flavor of an issue.
========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 11:57:00.00

ATT BODYPART TYPE:H

ATT CREATOR: Loreen M. Keller

ATT SUBJECT: HHS Hot issues for NY

ATT TO: Elizabeth E. Drye (DRYE_E)

ATT TO: Diana M. Fortuna (FORTUNA_D)

ATT CC: Stephen B. Silverman (SILVERMAN_S)

ATT CC: Anne E. McGuire (MCGUIRE_A)

TEXT:
Diana, this was HHS' original submission for New York -- we plan to edit this down somewhat -- call me at 62572 if you have particular questions or concerns. Thanks. Tennessee will follow for your review.
Lori
PRINTER FONT 12_POINT_ROMAN
MEMORANDUM TO ANNE McGUIRE
FROM: Mary Beth Donahue
RE: HHS Hot Issues -- NEW YORK
DATE: June 20, 1996

? Expiration of New York's Hospital Financing System: New York's hospital financing system is due to expire June 30, 1996. Legislation to continue the current system or establish a replacement has not been enacted, due to the impasse between the Governor and the State Legislature over the State's 1996

-1997 Budget. If New York State does not ratify new legislation that would continue the current system or put in place a new one, the State would move to a negotiated ratesetting system. This negotiated system is expected to reduce current hospital payment rates by approximately 35%. In anticipation that no legislation will be enacted by June 30, 1996, a representative from the Democratic

-lead NYS Assembly contacted HCFA for informal technical assistance on structuring their disproportionate share hospital (DSH) payments for low income patients and how to implement health care provider taxes for the period beginning July 1, 1996. New York is working on drafting revised Plan language that would meet the Federal DSH requirements. We do not yet know the specific type of taxes that New York may propose effective July 1, 1996.

? Ryan White CARE Title I Grants to New York: In late May, HHS announced that New York City would receive a $13 million in Ryan White CARE Title I grant. This is the final installment for FY 1996 funds and will make a final total of $92.1 million. This is about 12 percent less than HHS had estimated that New York would receive. On May 27, Representative Nita Lowey (D

-NY) wrote to the Secretary asking for an accounting of the discrepancy. On June 7, officials from HRSA and HHS met with staff of the New York delegation to explain that final Congressional action in holding harmless Title I cities in the formula, less discretionary funding was available for these grants. [In a related matter, Rep. Lowey also had written to the Secretary in December 1995 to seek assistance in retaining funding for some New York AIDS clinics whose funding had been terminated.]

? New Head Start Grantees: Early this month the ACF Regional Office awarded funds to 11 new grantees to expand Head Start services in New York City. The total amount of money

available is $4.2 million. Of the 11 programs selected for funding, four are located in Brooklyn, three in the Bronx, two in Queens, and one each in Manhattan and Staten Island. This distribution of services will help reach children across the city and counter

-balance the current concentration of Head Start resources in Manhattan. Successful applicants include major children's service providers and church

-based service providers.

? Welfare Reform: The State has submitted a waiver request for a statewide demonstration of fraud prevention and a 7

county Learnfare demonstration for AFDC children in grades
1

-6. (These provisions were part of a draft waiver package previously submitted to HHS. One of the key waivers requested was to allow a two

-tier benefit system for new arrivals to the State. HHS notified the State that it would not approve a two

-tier benefit waiver.)

On April 1 New York City began a new initiative for AFDC recipients called "NYC Way." Newcomers to JOBS will initially be assigned to Community Work Experience Program slots in NYC agencies (mainly in the Human Resources Administration and Health & Hospital Corporation). Only after 6 months' successful participation and a four week job search will they be considered for any other JOBS activity. The Democratic State Assembly is currently drafting a welfare reform proposal that is supposed to reflect the Clinton Administration's welfare proposal, including time limits. Numerous advocacy organizations have voiced their opposition to time limits being included in the Democrats' welfare proposal. The Republican State Senate is expected to support more conservative welfare legislation than the Governor is likely to support. The labor and religious communities have remained silent until a proposal is made public.

? Pending NYS Proposal for Child Welfare Waiver: Last summer the State of New York proposed, in response to an HHS announcement, a child welfare waiver for NYS that would shift federal funding more toward prevention and service provision for children and families, and away from out

-of

-home care. The waiver was envisioned as a way to extend some child welfare reforms already underway in NYS, and to permit a child welfare managed care program to begin in New York City. The Department has had initial discussions with NYS, but has not yet begun formal negotiations to see whether the State's waiver proposal could be approved by Secretary Shalala. The NYC managed care project is

currently held up by a temporary restraining order issued by a New York City court.

? Statewide Health Care Reform: The State of New York submitted a section 1115 statewide health care reform demonstration, entitled ?The Partnership Plan,? on March 20,

1995. The Plan would move approximately 2.7 million currently Medicaid eligible individuals and 300,000 Home Relief (General Assistance) beneficiaries into managed care. The Plan also proposes to establish new ?special needs plans? to serve individuals with HIV disease, seriously and persistently mentally ill adults, and seriously emotionally disturbed children. HCFA is discussing the following issues with the State: a phase

-in approach to implementation; a milestone approach for development of special needs plans; enrollment of HIV

-positive individuals; and budget neutrality. Draft terms and conditions have been developed and are under review in DHHS. If the demonstration is approved, the existing 1915(b) freedom of choice waivers will be subsumed by the section 1115 demonstration. The State has indicated that it may submit a 1915(b) waiver to implement the managed care portion of the Partnership Plan if HCFA does not approve the demonstration in the near future. In a letter to President Clinton dated May 30, 1996, Representative Susan Molinari is asking for a complete explanation of the status of the waiver and why it has not been granted. In addition, Representative Paxson recently issued a press release concerning delays in processing of the waiver.

========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 15:53:00.00

SUBJECT: New Protocol Records 06/21/96 (2 of 3)

TO: levi_j (levi_j@A1@CD) (WHO)
READ:24-JUN-1996 07:47:52.27

TEXT:
New Protocol Records 06/21/96
Part 2 of 3

****

PROTOCOL NUMBER: NIAID ACTG 273.

TITLE: A Phase I/II Study of HIVIG in Slowing Progression of Disease in HIV-Infected Children.

PHASE: Phase I / Phase II.

DISEASE STATUS:
Patients have the following symptoms and conditions: 1. HIV infection. 2. CD4 count > 200 cells/mm3 (ages 2-5 years) or > 100 cells/mm3 (age > 5 years). 3. Antiretroviral therapy for at least 6 months, with no change in regimen for at least 3 months prior to study entry. 4. Plasma ICD p24 >= 70 pg/ml that is stable or increasing prior to study entry.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients must have:
1. HIV infection.
2. CD4 count > 200 cells/mm3 (ages 2-5 years) or > 100 cells/mm3 (age > 5 years).
3. Antiretroviral therapy for at least 6 months, with no change in regimen for at least 3 months prior to study entry.
4. Plasma ICD p24 >= 70 pg/ml that is stable or increasing prior to study entry.
5. Life expectancy of at least 6 months.

AGE: 02 Years - 12 Years.
SEX: M. F.

REPRODUCTIVE SPECIFICATION:
Not pregnant.

WEIGHT:

< 45 kg.

PRIOR MEDICATION:
Required: Antiretroviral therapy for at least 6 months, with stable dose for at least 3 months.

CONCURRENT MEDICATION:
Required: PCP prophylaxis according to CDC guidelines.
Allowed:
1. Varicella-zoster immunoglobulin.
2. Hepatitis B immunoglobulin.
3. Prophylactic therapies not involving immunoglobulin.

LABORATORY VALUES AT ENTRY

CD4 (T4 CELL) COUNT: > 200 cells/mm3. (if ages two-five years) and > 100 cells/mm3 (if > five years). (100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus).

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients with the following prior condition are excluded:
History of severe reaction to IVIG.

AGE: 01 Days - 01 Years. 13 Years - 99 Years.

REPRODUCTIVE SPECIFICATION:
Pregnant.

WEIGHT:
>= 45 g.

RISK BEHAVIOR:
Ongoing drug or alcohol abuse.

PRIOR MEDICATION:
Excluded:
1. IVIG within the past 60 days.
2. Chemotherapy for an active malignancy within the past year.
3. MMR or rubella vaccinations within the past 6 months.
4. Intramuscular immunoglobulin within the past 60 days.

CONCURRENT MEDICATION:
Excluded:
1. IVIG.
2. Chemotherapy for an active malignancy.
3. MMR or rubella vaccinations.
4. Intramuscular immunoglobulin.

CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:
1. Severe diarrhea, nephrotic syndrome, or other protein-losing state that requires large doses of IVIG.
2. Any other condition requiring dosing with IVIG (e.g., ITP, hypogammaglobulinemia).
3. Acute illness with temperature >= 100 F and/or with IV antibiotics.
4. Grade 3 or worse clinical toxicities.
5. Unable to tolerate IV infusions at a minimum rate of 0.02 ml/kg/min.
6. Concomitant participation in an experimental antiretroviral or HIV vaccine trial.

GENERIC DRUG NAME

Drug 1: Anti-HIV immune serum globulin (Human). Immunomodulator.

DRUG TRADE NAME

Drug 1: HIVIG.

DRUG COMPANIES

Drug 1: North American Biologicals Incorporated
16500 Northwest 15th Avenue
Miami, FL 33169
Contact: Dr Christine Sapan (305) 625-5303.

END POINT

Toxicity, pharmacokinetic profile, efficacy.

DISCONTINUE TREATMENT

Patients discontinue treatment for the following reasons:
1. Unacceptable toxicity, including severe allergic reaction.
2. Clinical deterioration that requires change in antiretroviral regimen.
3. Inadequate compliance.
4. At request of parent or guardian, investigator, FDA, pharamaceutical sponsor, or NIAID Division of AIDS.

PARTICIPATING UNITS

0000001402:
UCLA Medical Center / Pediatric
10833 Le Conte Avenue / 22-404 MDCC
Los Angeles, CA 90095-1752
Contact: Leslie Spring (310) 206-6369
OPEN 960501 ACTU: 3601.

0000001410:
Long Beach Memorial / UCLA Medical Center
10833 Le Conte Avenue / 22-404 MDCC
Los Angeles, CA 90095-1752
Contact: Leslie Spring (310) 206-6369
OPEN 960501 ACTU: 3606.

0000001287:
Moffitt Hospital / UCSF
505 Parnassus Avenue / Box 0105 / M-601
San Francisco, CA 94143-0105
Contact: Debbie Trevithick (415) 476-6480
OPEN 960528 ACTU: 4501.

0000001395:
Children's Hospital of Oakland
747 52nd Street
Oakland, CA 94609-1809
Contact: Teresa Courville (510) 728-3885 X 2827
OPEN 960607 ACTU: 4504.

0000002205:
Children's Hosp of Washington DC / Children's Natl Med Ctr
111 Michigan Avenue NW / Suite 6112
Washington, DC 20010-2970
Contact: Sandra Jones (202) 884-3682
OPEN 960612 ACTU: 7101.

0000003235:
University of Florida Health Science Center / Pediatrics
653-1 West 8th Street
Jacksonville, FL 32209
Contact: Michelle Eagle (904) 549-3051
OPEN 960501 ACTU: 5051.

0000001368:
University of Miami School of Medicine / Pediatrics
1800 Northwest 10th Avenue / D-91
Miami, FL 33136
Contact: Brenda Haliburton-Jones (305) 548-4445
OPEN 960502 ACTU: 4201.

0000002298:
Baystate Medical Center of Springfield

759 Chestnut Street / SHU-Main 3
Springfield, MA 01199
Contact: Mari Pat Toye (413) 784-5399
OPEN 960516 ACTU: 7302.

0000002379:
University of Massachusetts Medical Center
55 Lake Avenue North
Worcester, MA 01655-0001
Contact: Joanne Shepard (508) 856-1692
OPEN 960516 ACTU: 7301.

0000001352:
Children's Hospital of Boston
300 Longwood Avenue / Carnegie Building / Third Floor
Boston, MA 02115
Contact: Robert Bishop (617) 355-8198
OPEN 960502 ACTU: 2901.

0000001353:
Boston City Hospital / Pediatrics
774 Albany Street / Finland Lab / Room 301
Boston, MA 02118
Contact: Anne Marie Regan (617) 534-5813
OPEN 960529 ACTU: 2903.

0000001274:
Children's Hospital of Michigan
3901 Beaubien Boulevard
Detroit, MI 48201
Contact: Charnell Cromer (313) 745-7857
OPEN 960607 ACTU: 5041.

0000001333:
Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl
15 South 9th Street
Newark, NJ 07107-2198
Contact: Dr Deborah Storm (201) 982-5066
OPEN 960514 ACTU: 2801.

0000001311:
Bellevue Hospital / New York University Medical Center
550 First Avenue
New York, NY 10016
Contact: Nagamah S Deygoo (212) 263-6426
OPEN 960606 ACTU: 4401.

0000001276:
Harlem Hospital Center
506 Lenox Avenue / Room 16-119
New York, NY 10037
Contact: Delia Calo (212) 939-4045
Contact: (212) 939-4043
OPEN 960501 ACTU: 5006.

0000001279:
North Shore University Hospital
865 Northern Boulevard / Suite 104
Great Neck, NY 11021
Contact: Emily Cupelli (516) 773-7676
OPEN 960509 ACTU: 5010.

0000001277:
SUNY / Health Sciences Center at Brooklyn
450 Clarkson Avenue / Box 49
Brooklyn, NY 11203
Contact: Savina Wiltshire (718) 270-3185
OPEN 960501 ACTU: 5008.

0000001423:
Children's Hospital at Albany Medical Center
47 New Scotland Avenue / A-111
Albany, NY 12208
Contact: Mary Ellen Adams (518) 262-6888
OPEN 960501 ACTU: 5042.

0000003520:
University of Rochester Medical Center
Box 689 / 601 Elmwood Avenue
Rochester, NY 14642
Contact: Barbara Murante (716) 275-5871
Contact: (716) 275-1549
OPEN 960520 ACTU: 1106.

0000001308:
Columbus Children's Hospital
700 Children's Drive
Columbus, OH 43205-2696
Contact: Jane Hunkler (614) 722-4460
OPEN 960606 ACTU: 2302.

0000001415:
Children's Hospital of Philadelphia
34th Street & Civic Center Boulevard
Philadelphia, PA 19104-4399
Contact: Deborah Schaible (215) 596-9138
OPEN 960607 ACTU: 6701.

0000002199:
Medical University of South Carolina
171 Ashley Avenue / 312 Clinical Science Building
Charleston, SC 29425-3312
Contact: Nadine Chavin (803) 792-2385 X 2123
OPEN 960606 ACTU: 5037.

0000002356:
Vanderbilt School of Medicine
A3310 Medical Center North

Nashville, TN 37232
Contact: Sandi Alls (615) 936-1245
OPEN 960507.

0000001270:
Saint Jude Children's Research Hospital of Memphis
332 North Lauderdale
Memphis, TN 38105-2794
Contact: Micki Roy (901) 495-3485
OPEN 960523 ACTU: 6501.

0000001420:
Children's Medical Center of Dallas
1935 Motor Street
Dallas, TX 75235
Contact: Diane Ross (214) 640-6198
OPEN 960516 ACTU: 5043.

0000001291:
Texas Children's Hospital / Baylor University
6621 Fannin Street / MC1-3291
Houston, TX 77030
Contact: Nancy Calles (713) 770-1319
OPEN 960514 ACTU: 3801.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 15:56:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I66CJQ81KW001TVL@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 15:53:16 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I66CMZEF2Y00007Z@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 15:55:53 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id PAA08456; Fri,
21 Jun 1996 15:55:08 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 12:36:00.00

SUBJECT: New Protocols 06/21/96 (1 of 3)

TO: levi_j (levi_j@A1@CD) (WHO)
READ:24-JUN-1996 07:47:37.49

TEXT:
June 14, 1996
1 of 3

NEW INFORMATION FROM ACTIS

The AIDS Clinical Trials Information Service (ACTIS) is a central resource providing current information on federally and privately sponsored clinical trials for AIDS patients and others infected with HIV. This service is a Public Health Service project produced collaboratively by the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institute of Allergy and Infectious Diseases, and the National Library of Medicine. NAC ONLINE, the computerized information service of the CDC National AIDS Clearinghouse, will alert you to any new information collected by ACTIS.

Descriptions of the 4 most recent clinical trials added to the ACTIS database are provided below.

For more information, call the ACTIS toll-free number to talk with a health specialist. On request, you can also obtain a printout of a customized search of the clinical trials databases. The information can also be accessed directly by subscribers through two online databases, AIDSTRIALS and AIDSDRUGS, available through the National Library of Medicine.

AIDS CLINICAL TRIALS INFORMATION SERVICE
1-800-TRIALS-A
(1-800-874-2572)
FAX: 1-301-738-6616
TTY/TDD: 1-800-243-7012
International Line: 1-301-217-0023

****

PROTOCOL NUMBER: NCI 95 C-184.

TITLE: Phase I Study of Levamisole in Children and Adolescents With Advanced Human Immunodeficiency Virus Infection.

PHASE: Phase I.

DISEASE STATUS:
Patients have the following symptoms and conditions: Advanced HIV infection.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients must have:
Advanced HIV infection.

AGE: 02 Years - 21 Years.
SEX: M. F.

LABORATORY VALUES AT ENTRY

CD4 (T4 CELL) COUNT: Unspecified cells/mm3.

PATIENT EXCLUSION CRITERIA

AGE: 01 Days - 01 Years. 22 Years - 99 Years.

GENERIC DRUG NAME

Drug 1: Levamisole hydrochloride. Immunomodulator.
Drug 2: Zidovudine. Antiretroviral.
Drug 3: Didanosine. Antiretroviral.

DRUG TRADE NAME

Drug 1: Ergamisol.
Drug 2: Retrovir.
Drug 3: Videx.

DRUG COMPANIES

Drug 1: Janssen Research Foundation
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200
Contact: Professional Services Depart (800) 253-3682.

Drug 2: Glaxo Wellcome
5 Moore Drive / PO Box 13398
Research Triangle Park, NC 27709
Contact: Department of Consumer Affairs (800) 437-0992 X 7900.

Drug 3: Bristol - Myers Squibb Company
2400 West Lloyd Expressway
Evansville, IN 47721-0001
Contact: Information (800) 662-7999.

PARTICIPATING UNITS

0000001821:
National Cancer Institute
9000 Rockville Pike / Clinical Center
Bethesda, MD 20892
Contact: Susan Sandelli (301) 402-1391
Contact: (301) 402-1387
OPEN / USA accrual 951201.

****

PROTOCOL NUMBER: NCI 95 C-192.

TITLE: Phase I Protocol for the Administration of 2'-beta-Fluoro-2',3'-Dideoxyadenosine (F-ddA) to Patients With HIV-Associated Diseases.

PHASE: Phase I.

DISEASE STATUS:
Patients have the following symptoms and conditions: 1. Symptomatic HIV infection or AIDS. 2. CD4 count 100-400 cells/mm3.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients must have:
1. Symptomatic HIV infection or AIDS.
2. CD4 count 100-400 cells/mm3.
3. Ambulatory status.
4. Life expectancy greater than 3 months.

AGE: 18 Years - 65 Years.
SEX: M. F.

REPRODUCTIVE SPECIFICATION:
Not pregnant. Negative pregnancy test. Not breast-feeding. Abstinence or effective method of birth control /contraception during the study and for 60 days after.

LABORATORY VALUES AT ENTRY

HEMOGLOBIN: >= 9.0 g/dl. (men); >= 8.8 g/dl (women).

PLATELET COUNT: >= 75000 platelets/mm3.
CD4 (T4 CELL) COUNT: 100 - 400 cells/mm3. (100 - 200 - 300 - 400).
BILIRUBIN: <= 2 x ULN mg/dl. (ULN = upper limit of normal).
SGOT (AST): <= 2 x ULN.
CREATININE: <= 1.5 mg/dl.
CREATININE CLEARANCE: >= 50 ml/min. /1.73 m2.
OTHER LABORATORY VALUES: Absolute neutrophils: >= 1000 cells/mm3. Alkaline phosphatase: <= 2 x ULN. Amylase <= 1.5 x ULN (unless predominantly salivary amylase upon fractionation). Lipase <= 1.5 x ULN. Triglycerides <= 750 mg/dl.

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients with the following prior conditions are excluded:
1. Prior hepatic cirrhosis.
2. Prior cardiomyopathy or other significant cardiac disease.
3. Prior pancreatitis.

AGE: 01 Days - 17 Years. 66 Years - 99 Years.

REPRODUCTIVE SPECIFICATION:
Pregnant. Positive pregnancy test. Breast-feeding. No abstinence or no agreement to use effective method of birth control during study and for 60 days after.

PRIOR MEDICATION:
Excluded within the past 3 weeks: Antiretrovirals.
Excluded within the past 2 weeks: Acute treatment for a serious infection or for any AIDS-defining opportunistic infection.
Excluded within the past 4 weeks:
1. Cytotoxic chemotherapy.
2. Steroids.
3. Interferon.
4. Immunomodulators.
5. Any investigational drugs.

CONCURRENT MEDICATION:
Excluded:
1. Foscarnet.
2. Ganciclovir.

CO-EXISTING CONDITIONS OR DISEASES:
Patients with the following symptoms and conditions are excluded:
1. Hepatic dysfunction.
2. Evidence of cardiomyopathy or other significant cardiac disease.
3. Grade 2 peripheral neuropathy.
4. Active life-threatening infection (other than HIV).

5. Kaposi's sarcoma or other tumor that is likely to require cytotoxic anti-tumor therapy within the next 6 months.
6. Severe malabsorption.

GENERIC DRUG NAME

Drug 1: 2-Fluoro-2',3'-dideoxyadenosine. Antiviral.

DRUG TRADE NAME

Drug 1: F-ddA.

DRUG COMPANIES

Drug 1: Drugs are provided by each participating unit site

.

END POINT

MTD or plateau of drug activity.

DISCONTINUE TREATMENT

Patients discontinue treatment for the followings reasons:
1. Unacceptable toxicity.
2. General debilitation or mental incapacity that would preclude informed consent.

PARTICIPATING UNITS

0000003536:
National Cancer Institute
9000 Rockville Pike / Clinical Center
Bethesda, MD 20892
Contact: Jill Lietzau (800) 772-5464 X 607
OPEN / USA accrual 960517.

****

PROTOCOL NUMBER: NCI 96 C-4.

TITLE: Phase II Study of Oral Thalidomide for Patients With HIV Infection and Kaposi's Sarcoma.

PHASE: Phase II.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV infection. 2. Extra-pulmonary, non-life-threatening Kaposi's sarcoma that has progressed over the past 2 months. 3. Evaluable disease by noninvasive methods. 4. At least 5 measurable lesions that have never received local therapy. (Actively bleeding or critically located lesions must not pose an immediate risk.) 5. On a stable dose of antiretroviral therapy unless considered not medically indicated.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:

Patients must have:

1. HIV infection.
2. Extra-pulmonary, non-life-threatening, progressive, Kaposi's sarcoma.
3. Evaluable disease with at least 5 lesions that have not received local therapy.
4. Stable antiretroviral therapy unless considered not medically indicated.
5. Life expectancy greater than 3 months.

AGE: 18 Years - 99 Years.
SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Not pregnant. Negative pregnancy test. Abstinence or agree to use both barrier and hormonal methods of birth control / contraception until 4 weeks after study.

PRIOR MEDICATION:

Required (unless not medically indicated): stable dose of antiretroviral therapy for the past 2 weeks.

CONCURRENT MEDICATION:

Required (unless not medically indicated): stable dose of antiretroviral therapy.

LABORATORY VALUES AT ENTRY

HEMOGLOBIN: >= 8.0 g/dl. (or transfusion within past month).
PLATELET COUNT: >= 70000 platelets/mm3.
CD4 (T4 CELL) COUNT: Unspecified cells/mm3.
BILIRUBIN: <= 2.0 mg/dl.

SGOT (AST): <= 125 units/l.
CREATININE: <= 1.5 mg/dl.
CREATININE CLEARANCE: >= 70 ml/min. /1.73 m2.
OTHER LABORATORY VALUES: Absolute neutrophils: > 750 cells/mm3. APTT or PT: <= 120 percent of control.

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients with the following prior conditions are excluded:
1. History of hepatic cirrhosis.
2. History of tumors or malignancies other than KS, except for malignancies that have been in complete remission for at least 1 year or completely resected basal cell carcinoma of the skin.
3. Underlying severe or life-threatening infection within the past 2 weeks.
4. Fever (39 C or greater) within the past 10 days unless not caused by a severe, underlying infection.

AGE: 01 Days - 17 Years.

REPRODUCTIVE SPECIFICATION:
Pregnant. Positive pregnancy test. No abstinence or no agreement to use both barrier and hormonal methods of birth control / contraception.

RISK BEHAVIOR:
Unwilling to refrain from unprotected sexual contact or other activities that may cause re-infection with HIV.
Unwilling to refrain from sedating recreational drugs or alcohol.

PRIOR TREATMENT:
Excluded within past month:
1. Radiation therapy.
2. Intralesional injections or other local treatment modalities.

PRIOR MEDICATION:
Excluded within the past 6 months: suramin.
Excluded since the onset of KS: thalidomide.
Excluded within the past month:
1. Cytotoxic chemotherapeutic agents.
2. Interferon.
3. Other systemic anti-KS agents or regimens.
4. Systemic steroids (except for physiologic replacment doses of corticosteroids).

CONCURRENT MEDICATION:
Excluded:
1. Other specific KS therapy during the first 6 months of study.
2. Drugs with sedating activity, unless taken in minimal doses.

CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:
1. Grade 2 or worse peripheral neuropathy, except for localized neuropathy due to a mechanical cause or trauma.
2. Current tumors or malignancies other than KS.
3. Grade 3 or worse toxicity other than lymphopenia or neutropenia.
4. Known hypersensitivity to thalidomide or related compounds.

GENERIC DRUG NAME

Drug 1: Thalidomide. Immunomodulator.

DRUG COMPANIES

Drug 1: Drugs are provided by each participating unit site

DISCONTINUE TREATMENT

Patients discontinue treatment for the following reasons:
1. Number of lesions doubles.
2. New or progressive visceral disease requiring standard therapy.
3. Tumor-associated edema or effusions that appear or worsen and require standard therapy.
4. Other changes in condition that preclude further thalidomide therapy.
5. Irreversible grade 3 or any grade 4 nonhematologic toxicity, unless deemed unrelated to thalidomide.
6. Pregnancy or lack of willingness to use recommended contraception.

PARTICIPATING UNITS

0000003539:
National Cancer Institute
9000 Rockville Pike / Clinical Center
Bethesda, MD 20892
Contact: Kathy Wyvill (800) 772-5464 X 507
OPEN / USA accrual 960213.

****

PROTOCOL NUMBER: NIAID 96 HG-51.

TITLE: Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Antisense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical

Twins.

PHASE: Phase I / Phase II.

DISEASE STATUS:
Patients have the following symptoms and conditions: 1. HIV seropositive, with a healthy, HIV seronegative identical twin.
2. CD4 count > 50 cells/mm3 in the HIV-infected patient.

PATIENT INCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients must have:
1. HIV seropositivity.
2. CD4 count > 50 cells/mm3.
3. A healthy, HIV seronegative identical twin donor who is available for apheresis throughout the study.

AGE: 18 Years - 99 Years.
SEX: M. F.

REPRODUCTIVE SPECIFICATION:
Not pregnant.

LABORATORY VALUES AT ENTRY

CD4 (T4 CELL) COUNT: > 50 cells/mm3. (100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus).

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:
Patients with the following prior condition are excluded:
History of lymphoma.

AGE: 01 Days - 17 Years.

REPRODUCTIVE SPECIFICATION:
Pregnant.

CONCURRENT MEDICATION:
Excluded in recipient twin: Systemic KS therapy.

CO-EXISTING CONDITIONS OR DISEASES:
Patients with the following symptoms or conditions are excluded:
Acute or acutely progressing disease processes.
Donor twins with the following symptoms or conditions are excluded:
1. Unstable medical condition that would preclude apheresis.
2. Seropositive for CMV or EBV, if recipient is negative for these.
3. Positive for active or suspected hepatitis B or C.

GENERIC DRUG NAME

Drug 1: Lymphocytes, Activated. Immunomodulator.

DRUG COMPANIES

Drug 1: Drugs are provided by each participating unit site.

PARTICIPATING UNITS

0000003153:
National Institute of Allergy & Infectious Diseases
9000 Rockville Pike / Clinical Center / Room 11C304
Bethesda, MD 20892
Contact: Unspecified (800) 243-7644
OPEN / USA accrual 960412.

****

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 12:40:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <011665NFVUDS001NJ0@PMDF.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 12:36:13 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <011665QOXXK400007Z@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 21 Jun 1996 12:38:50 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA24163; Fri,
21 Jun 1996 12:38:05 -0400
Errors-to: martha_vander_kolk@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 16:46:00.00

SUBJECT: parking

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:23-JUN-1996 16:54:44.75

TO: Deborah Parham (DPARHAM@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
Jeff-space 212, level 3

Deborah-North Lot, next to visitor's space 132
========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 16:54:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01166EEEALDS001RHB@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Fri, 21 Jun 1996 16:46:13 -0400 (EDT)
Received: from PCC.SSW.DHHS.GOV (ibm.pcc.dhhs.gov)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01166EHOJJRO00007Z@STORM.EOP.GOV> for
LEVI_J@A1.EOP.GOV; Fri, 21 Jun 1996 16:48:54 -0700 (MST)
Received: from HRSA.SSW.DHHS.GOV by PCC.SSW.DHHS.GOV
(Soft*Switch Central V4L380P7) id 112747160096173FHRSA; Fri,
21 Jun 1996 16:38:16 -0400 (EDT)
Comment: MEMO 1996/06/21 16:54
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-JUN-1996 11:36:32.44

SUBJECT: RE: SSA mailing

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 11:46:34.73

CC: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:08:05.53

TEXT:
yes...I'll call them next week.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:21-JUN-1996 12:33:42.51

SUBJECT: Leslie Hardy called

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUN-1996 16:51:30.66

TEXT:
She was looking for information on the impact of Medicaid changes on persons with HIV. Told her you'd be back Monday.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: KSF@s-3.com@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 09:15:00.00

SUBJECT: Re: letterhead

TO: Jeffrey Levi (LEVI_J@A1@CD) (WHO)
READ:21-JUN-1996 11:24:52.14

TEXT:

It's on its way.....

|From: Jeffrey Levi
|To: KSF
|Subject: letterhead
|Date: Thursday, June 20, 1996 12:04PM
|
| Would it be possible for you to fed ex to me a few sheets of the
| Advisory Council letterhead -- I need to get some stuff out for
| Scott that should be on letterhead -- thanks (unless there is a
| macro or something to do it from the computer -- but I doubt our
| software would know how).
|
|
========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 09:18:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I65YO1CG7K000WHQ@PMDF.EOP.GOV> for
LEVI_J@a1.eop.gov; Fri, 21 Jun 1996 09:15:52 -0400 (EDT)
Received: from ssshq5.s-3.com (206.65.240.10)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I65YRBSDDO00007Z@STORM.EOP.GOV> for
LEVI_J@a1.eop.gov; Fri, 21 Jun 1996 09:18:32 -0700 (MST)
X-Mailer: Worldtalk (NetConnex V4.00a)/MIME
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:21-JUN-1996 10:38:07.00

SUBJECT: Administrative Requests

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:21-JUN-1996 10:43:46.40

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-JUN-1996 10:50:55.36

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:04:21.44

TO: Dennis Burke (BURKE_D) (OPD)
READ:21-JUN-1996 13:16:39.53

TO: Diane Regas (REGAS_D) (OPD)
READ:21-JUN-1996 10:38:55.85

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 10:02:41.64

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 10:39:47.31

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-JUN-1996 08:45:42.04

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:21-JUN-1996 12:03:39.74

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:21-JUN-1996 11:36:48.65

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:21-JUN-1996 11:38:46.46

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:21-JUN-1996 11:27:33.80

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:21-JUN-1996 12:10:03.62

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:21-JUN-1996 10:48:33.59

TEXT:
Now that Ros is back, please resume taking administrative requests --e.g. pagers, computer service etc. -- to her instead of to to Ashley/OA directly.

Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)

CREATION DATE/TIME:21-JUN-1996 16:42:08.40

SUBJECT: party -- marsha

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 10:05:11.07

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUN-1996 16:53:56.94

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-JUN-1996 19:10:04.75

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 13:06:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Paul Yandura

ATT SUBJECT: come to the party!!!

ATT TO: Dorothy L. Karayannis (KARAYANNIS_D)

ATT TO: Philip G. Dufour (DUFOUR_P)

ATT TO: Douglas S. Sheorn (SHEORN_D)

ATT TO: David L. Plummer (PLUMMER_D)

ATT TO: Thomas A. Shea (SHEA_T)

ATT TO: C. Wayne Skinner (SKINNER_C)

ATT TO: Miguel M. Bustos (BUSTOS_M)

ATT TO: Daniel Rader (RADER_D)

TEXT:

========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========
ATT CREATION TIME/DATE:20-JUN-1996 19:11:00.00

ATT CREATOR: Amanda Crumley

ATT SUBJECT: Party for three departures...

ATT TO: Karen L. Hancox (HANCOX_K)

ATT TO: Gordon Li (LI_G)

ATT TO: Daniel E. Bernal (BERNAL_D)

ATT TO: Wendy L. Smith (SMITH_WL)

ATT TO: Eric Eve (EVE_E)

ATT TO: Ray Martinez (MARTINEZ_R)

ATT TO: Cookab Hashemi (HASHEMI_C)

ATT TO: David Wofford (WOFFORD_D)

ATT TO: Deborah L. Fine (FINE_D)

ATT TO: Paul Yandura (YANDURA_P)

ATT TO: Douglas B. Sosnik (SOSNIK_D)

ATT TO: Craig Gardenswartz (GARDENSWAR_C)

ATT TO: Nancy V. Hernreich (HERNREICH_N)

ATT TO: Rebecca A. Cameron (CAMERON_RA)

ATT TO: Betty Currie (CURRIE_B)

ATT TO: Debra A. Schiff (SCHIFF_D)

ATT TO: Maureen F. Lewis (LEWIS_M)

ATT TO: Patricia A. McHugh (MCHUGH_P)

ATT TO: Molly Varney (VARNEY_M)

ATT TO: Jennifer Palmieri (PALMIERI_J)

ATT TO: Janice A. Enright (ENRIGHT_J)

ATT TO: John O. Sutton (SUTTON_J)

ATT TO: Jennifer M. O'Connor (OCONNOR_J)

ATT TO: Shana E. Tesler (TESLER_S)

ATT TO: Karin J. Abramson (ABRAMSON_K)

ATT TO: Laura Capps (CAPPS_L)

ATT TO: Steven A. Cohen (COHEN_SA)

ATT TO: Angus S. King (KING_A)

ATT TO: Julia Moffett (MOFFETT_J)

ATT TO: Gabrielle M. Bushman (BUSHMAN_G)

ATT TO: Brenda B. Costello (COSTELLO_B)

ATT TO: Kris Balderston (BALDERSTON_K)

ATT TO: Stephen B. Silverman (SILVERMAN_S)

ATT TO: Russell W. Horwitz (HORWITZ_R)

ATT TO: David S. Beaubaire (BEAUBAIRE_D)

ATT TO: Anne E. McGuire (MCGUIRE_A)

ATT TO: Loreen M. Keller (KELLER_L)

ATT TO: Evan M. Ryan (RYAN_E)

ATT TO: Alice J. Pushkar (PUSHKAR_A)

ATT TO: Lana Dickey (DICKEY_L)

ATT TO: dickey (ROBYN_D)

ATT CC: Robyn G. Dickey (DICKEY_R)

ATT CC: Lana Dickey (DICKEY_L)

ATT CC: Tracy B. LaBrecque (LABRECQUE_T)

ATT CC: Kim B. Widdess (WIDDESS_K)

ATT CC: Jennifer D. Dudley (DUDLEY_J)

ATT CC: Stephen R. Neuwirth (NEUWIRTH_S)

ATT CC: Robert W. Schroeder III (SCHROEDER_R)

ATT CC: Kathleen M. Whalen (WHALEN_K)

ATT CC: John P. Hart (HART_J)

ATT CC: John B. Emerson (EMERSON_J)

ATT CC: Kevin M. O'Keefe (OKEEFE_K)

ATT CC: Sky M. Gallegos (GALLEGOS_S)

ATT CC: Megan B. Williams (WILLIAMS_M)

ATT CC: Alison Bracewell (BRACEWELL_A)

ATT CC: Timothy J. Keating (KEATING_T)

ATT CC: Christopher F. Walker (WALKER_C)

ATT CC: Stacey L. Rubin (RUBIN_S)

ATT CC: Paul R. Carey (CAREY_P)

ATT CC: Tracey E. Thornton (THORNTON_T)

ATT CC: Lucia A. Wyman (WYMAN_L)

ATT CC: Ann M. Cattalini (CATTALINI_A)

ATT CC: Jodie R. Torkelson (TORKELSON_J)

ATT CC: Kelli R. McClure (MCCLURE_K)

ATT CC: Christopher M. Gruin (GRUIN_C)

ATT CC: Ian R. Van Praagh (VANPRAAGH_I)

ATT CC: Ronald K. Saleh (SALEH_R)

ATT CC: Kim Holmes (HOLMES_K)

ATT CC: Madge H. Henning (HENNING_M)

ATT CC: Marilyn R. Jacanin (JACANIN_M)

ATT CC: Robert S. Weiner (WEINER_R)

ATT CC: Lori A. Wiener (WIENER_L)

ATT CC: James M. Teague (TEAGUE_J)

ATT CC: Melinda N. Bates (BATES_M)

ATT CC: Ann McCoy (MCCOY_A)

ATT CC: Marc A. Hoberman (HOBERMAN_M)

ATT CC: Holly H. Holt (HOLT_H)

ATT CC: Miguel M. Bustos (BUSTOS_M)

ATT CC: C. Wayne Skinner (SKINNER_C)

ATT CC: Aprill Springfield (SPRINGFIELD_)

ATT CC: C. Patricia Cogdell (COGDELL_C)

ATT CC: Bob J. Nash (NASH_B)

ATT CC: Phu D. Huynh (HUYNH_P)

ATT CC: Guild L. Taylor (TAYLOR_G)

ATT CC: Susan McNay (MCNAY_S)

ATT CC: Alan R. Einisman (EINISMAN_A)

ATT CC: Charles N. Duncan (DUNCAN_C)

ATT CC: David L. Plummer (PLUMMER_D)

ATT CC: Julia R. Green (GREEN_J)

ATT CC: Julie E. Mason (MASON_J)

ATT CC: Joshua Silverman (SILVERMAN_J)

ATT CC: Rica F. Rodman (RODMAN_R)

ATT CC: A. Victoria Rivas-Vazquez (RIVASVAZQU_A)

ATT CC: Nicole Elkon (ELKON_N)

ATT CC: Lucie F. Naphin (NAPHIN_L)

ATT CC: Patrick M. Steel (STEEL_P)

ATT CC: Sara Grote (GROTE_S)

ATT CC: Alexis M. Herman (HERMAN_A)

ATT CC: Ruby G. Moy (MOY_R)

ATT CC: Holly Carver (CARVER_H)

ATT CC: Doris O. Matsui (MATSUI_D)

ATT CC: Marilyn Yager (YAGER_M)

ATT CC: Betsy Myers (MYERS_B)

ATT CC: Lisa Ross (ROSS_LI)

ATT CC: Lee A. Satterfield (SATTERFIEL_L)

ATT CC: Floydetta McAfee (MCAFEE_F)

ATT CC: Marilyn DiGiacobbe (DIGIACOBBE_M)

ATT CC: Jay K. Footlik (FOOTLIK_J)

ATT CC: Robert B. Johnson (JOHNSON_R)

ATT CC: Suzanna Valdez (VALDEZ_S)

ATT CC: Daniel Wexler (WEXLER_D)

ATT CC: William White (WHITE_WI)

ATT CC: Ann T. Eder (EDER_A)

ATT CC: Christa T. Robinson (ROBINSON_C)

ATT CC: Brian Scott (SCOTT_B)

ATT CC: Jennifer O. Jose (JOSE_J)

ATT CC: Holly B. Nichols (NICHOLS_H)

ATT CC: Margo L. Spiritus (SPIRITUS_M)

ATT CC: Anne Hawley (HAWLEY_A)

ATT CC: Stephanie Streett (STREETT_S)

ATT CC: Peter A. Selfridge (SELFRIDGE_P)

ATT CC: Ronald W. Books (BOOKS_R)

ATT CC: Laura A. Graham (GRAHAM_L)

ATT CC: Ellen W. McCathran (MCCATHRAN_E)

ATT CC: Andrew Friendly (FRIENDLY_A)

ATT CC: Paige E. Reffe (REFFE_P)

ATT CC: Kelly Craighead (CRAIGHEAD_K)

ATT CC: Catherine A. Cornelius (CORNELIUS_C)

ATT CC: Dan Rosenthal (ROSENTHAL_D)

ATT CC: John B. Emerson (EMERSON_J)

ATT CC: Jim Loftus (LOFTUS_J)

ATT CC: Kara M. McGuire (MCGUIRE_K)

ATT CC: Sam Myers (MYERS_S)

ATT CC: Jaycee A. Pribulsky (PRIBULSKY_J)

ATT CC: Todd Stern (STERN_T)

ATT CC: Phillip M. Caplan (CAPLAN_P)

ATT CC: Helen P. Howell (HOWELL_H)

ATT CC: David S. Goodin (GOODIN_D)

ATT CC: Sharon E. Wagner (WAGNER_S)

ATT CC: Carolyn E. Cleveland (CLEVELAND_C)

ATT CC: James A. Dorskind (DORSKIND_J)

ATT CC: Daniel W. Burkhardt (BURKHARDT_D)

ATT CC: Debra D. Bird (BIRD_D)

ATT CC: Stephen R. Nolet (NOLET_S)

ATT CC: Janice H. Vranich (VRANICH_J)

ATT CC: Melanie F. Pearlman (PEARLMAN_M)

ATT CC: Michelle A. Houston (HOUSTON_M)

ATT CC: Lori E. Abrams (ABRAMS_L)

ATT CC: Lori K. Krause (KRAUSE_L)

ATT CC: Stephen K. Horn (HORN_S)

ATT CC: Charlene C. Cozart (COZART_C)

ATT CC: Susan Beveridge (BEVERIDGE_S)

ATT CC: Helen M. Stefanopoulos (STEFANOPOU_H)

ATT CC: Amanda C. Draper (DRAPER_A)

ATT CC: Robin Willis (PR_U=RWILLIS@PR_L=DSUOEOB@MRP@OPUS)

ATT CC: Talieb N. Wills (WILLS_T)

ATT CC: Kathleen A. Barry (BARRY_K)

ATT CC: Sarah H. Brau (BRAU_S)

ATT CC: Karen C. Fahle (FAHLE_K)

ATT CC: Nathan A. Marceca (MARCECA_N)

ATT CC: Lori K. Krause (KRAUSE_L)

ATT CC: Mary L. Maddox (MADDOX_M)

ATT CC: Robert C. Houser (HOUSER_R)

ATT CC: Patrick E. Briggs (BRIGGS_P)

ATT CC: Jamie S. Williams (WILLIAMS_JS)

ATT CC: Jack R. Shock (SHOCK_J)

ATT CC: Maureen A. Hudson (HUDSON_M)

ATT CC: Jeff P. Dailey (DAILEY_J)

ATT CC: Julia F. Bator (BATOR_J)

ATT CC: Kyle M. Baker (BAKER_K)

ATT CC: Diane Ikemiyashiro (IKEMIYASHI_D)

ATT CC: Leanne Johnson (JOHNSON_L)

ATT CC: Seth E. Masket (MASKET_S)

ATT CC: Tracy F. Sisser (SISSER_T)

ATT CC: Chance Curtis (PR_U=CCURTIS@PR_L=RMD399@MRP@OPUS)

ATT CC: Emily J. Curtis (CURTIS_E)

ATT CC: Carmen B. Fowler (FOWLER_C)

ATT CC: Catherine T. Kitchen (KITCHEN_C)

ATT CC: Eileen M. Upperman (UPPERMAN_E)

ATT CC: Lynn A. Crable (CRABLE_L)

ATT CC: Eunice C. Hendrix (HENDRIX_E)

ATT CC: Christine K. Baer (BAER_C)

ATT CC: Debra S. Wood (WOOD_D)

ATT CC: Roger Goldblatt (GOLDBLATT_R)

ATT CC: Terry W. Good (GOOD_T)

ATT CC: Lee R. Johnson (JOHNSON_LR)

ATT CC: Heather M. Marabeti (MARABE_H)

ATT CC: Elizabeth J. Cotham (COTHAM_E)

ATT CC: Joel Velasco (VELASC_J)

ATT CC: Ashley K. Adams (ADAMS_A)

ATT CC: Michael J. Burton (BURTON_M)

ATT CC: Karren E. Skelton (SKELTO_K)

ATT CC: Eric R. Anderson (ANDERS_E)

ATT CC: Michael B. Feldman (FELDMA_M)

ATT CC: Christopher R. Ulrich (ULRICH_C)

ATT CC: Lee Ann Brackett (BRACKE_L)

ATT CC: Skila S. Harris (HARRIS_S)

ATT CC: Peggy Cusack (CUSACK_P)

ATT CC: Lisa A. Berg (BERG_L)

ATT CC: John Donoghue (DONOGH_J)

ATT CC: Jaqueline A. Dycke (DYCKE_J)

ATT CC: Joseph T. Keohan (KEOHAN_J)

ATT CC: Douglas R. Matties (MATTIES_D)

ATT CC: Ashley L. Raines (RAINES_A)

ATT CC: Signe G. Rhea (RHEA_S)

ATT CC: Cheryl A. Reynolds (REYNOLDS_C)

ATT CC: Jeter A. Morris (MORRIS_J)

ATT CC: Ann M. O'Leary (OLEARY_A)

ATT CC: Catherine A. Cornelius (CORNELIUS_C)

ATT CC: Douglas Band (BAND_D)

ATT CC: Karin Kullman (KULLMAN_K)

TEXT:
As most of you may know, Donald Dunn, Wendy Heistad and Marsha Scott are departing the White House for the Windy City... yes they are all three leaving us to work on the convention in Chicago. Since all three have been a very integral part of our lives here at the White House, we want to bid them a proper farewell -- and we are... The Office of Political Affairs is throwing a farewell party for Donald, Wendy and Marsha tomorrow afternoon at 4:00 in

Rm. 115 of the OEOB. This is a surprise (har har), so please try to keep it under wraps until 4:01 when we parade them in! If you have any questions, please call Amanda Crumley or Stacy Forster at x66257.
We hope to see you all there -- please spread the word in the event that we may have missed someone.....
(check out the distribution list.. these guys have a lot of friends!)

See you there,
Amanda and Stacy
========== END ATTACHMENT 2 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Diana M. Fortuna (FORTUNA_D) (OPD)

CREATION DATE/TIME:21-JUN-1996 10:05:38.55

SUBJECT: RE: SSA mailing

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:21-JUN-1996 11:36:05.92

CC: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:04:11.78

TEXT:
Do you mean the list of people we were pretty impressed with?
Shouldn't we at least complain to SSA?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Rosalyn A. Miller (MILLER_RA) (OPD)

CREATION DATE/TIME:21-JUN-1996 15:57:47.83

SUBJECT: Kathi Way

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:24-JUN-1996 16:44:05.92

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:21-JUN-1996 19:09:35.95

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:24-JUN-1996 09:13:05.13

TO: Dennis Burke (BURKE_D) (OPD)
READ:21-JUN-1996 16:14:54.05

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:25-JUN-1996 12:24:58.23

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:21-JUN-1996 19:19:12.31

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUN-1996 10:03:50.26

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:21-JUN-1996 16:09:26.21

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:27-JUN-1996 08:46:28.38

TO: Dorothy L. Karayannis (KARAYANNIS_D) (OPD)
READ:21-JUN-1996 16:40:20.75

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:21-JUN-1996 17:02:22.29

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUN-1996 16:53:37.28

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:21-JUN-1996 15:58:52.91

TO: Bruce N. Reed (REED_B) (WHO)
READ:21-JUN-1996 16:14:49.22

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:21-JUN-1996 16:19:21.63

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:21-JUN-1996 17:23:20.53

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:24-JUN-1996 10:14:08.00

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:21-JUN-1996 16:04:32.40

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:21-JUN-1996 16:27:26.64

TEXT:
Kathi called today and wonders if anyone is able/willing to do a WW tour on Monday night. Please let me know if you are available/willing.
Thanks

Withdrawal/Redaction Marker
Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
005. email	From: DOBER@HRSA.SSW.DHHS.GOV, To: Multiple Recipients, Re: Reference Check Assignments [partial] (1 page)	06/21/1996	b(6)

COLLECTION:
Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:
[06/18/1996 - 06/23/1996]

2018-0759-F
jn418

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.
PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).
RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: DOBER@HRSA.SSW.DHHS.GOV@INET@EOPMRX

CREATION DATE/TIME:21-JUN-1996 09:39:00.00

SUBJECT: reference check assignments

TO: LEVI_J (LEVI_J@A1@CD) (WHO)
READ:21-JUN-1996 11:35:32.64

TO: Deborah A. Willis (DWILLIS@PHSCHI.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: Audrey H. Nora (ANORA@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TO: Deborah Parham (DPARHAM@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

CC: CALVIN ADAMS (CADAMS@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

CC: DENNIS MALCOMSON (DMALCOMS@HRSA.SSW.DHHS.GOV@INET@EOPMRX)
READ:NOT READ

TEXT:
I have placed calls to those without references. Hopefully I will receive them by today.

(b)(6) Nora and Levi

(b)(6) Nora and Parham

[005]

(b)(6) Garcia and Parra

(b)(6) McCurdy and Willis

(b)(6) will have to be rescheduled. Her secretary gave me the time slot without her approval.

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 09:41:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01165ZGSK5XS001KZG@PMDF.EOP.GOV> for LEVI_J@a1.eop.gov; Fri, 21 Jun 1996 09:39:03 -0400 (EDT)
Received: from PCC.SSW.DHHS.GOV (ibm.pcc.dhhs.gov)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01165ZK15DHO00007Z@STORM.EOP.GOV> for LEVI_J@A1.EOP.GOV; Fri, 21 Jun 1996 09:41:42 -0700 (MST)

Received: from HRSA.SSW.DHHS.GOV by PCC.SSW.DHHS.GOV
(Soft*Switch Central V4L380P7) id 931840090096173FHRSA; Fri,
21 Jun 1996 09:33:09 -0400 (EDT)
Comment: MEMO 1996/06/21 09:47
========== END ATTACHMENT 1 ==========

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-JUN-1996 16:53:32.33

SUBJECT: fyi

TO: Remote Addressee (wepaul@nih.gov@INET)
READ:NOT READ

TEXT:

========== ATTACHMENT 1 ==========
ATT CREATION TIME/DATE:21-JUN-1996 15:01:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Weniger, Bruce

ATT SUBJECT: Re: Re[2]: PACHA vaccine recommendations

ATT TO: bolog003 (bolog003@mc.duke.edu@INET@EOPMRX)

ATT TO: WEPaul (WEPaul@helix.nih.gov@INET@EOPMRX)

ATT CC: Fogel, Robert (Chicago) (BigBob411@aol.com@INET@EOPMRX)

ATT CC: Miramontes, Helen (UCSF.itsa) (helenmm@itsa.ucsf.edu@INET@EOPMRX)

ATT CC: 'Levine, Alexandra (c/o Hornor)' (hornor@hsc.usc.edu@INET@EOPMRX)

ATT CC: 'Levi, Jeff (ONAP, White House)' (LEVI_J@A1@CD)

ATT CC: Cade, Jerry (Nevada) (peacevisio@aol.com@INET@EOPMRX)

ATT CC: 'Hitt, R. Scott (Los Angeles)' (scotthitt@aol.com@INET@EOPMRX)

ATT CC: Anderson, Terje (Vermont) (TANDERS@vdhvax.vdh.state.vt.us@INET@EOPMRX)

TEXT:

Dear Dani,
Thanks for your comment below. Our committee recognizes that we have not had an opportunity to consider this issue with the benefit of your panel's complete report in hand, as we had hoped to do by last April.

There is much that we might say regarding what NIH ought to do, as you suggest, but we felt it wise to defer doing so until we had all the relevant
material available from the basic science community which considered this question as part of the Levine Committee process, as well as input from the

public health and international communities. It clearly will be high on our future
agenda to have more thorough briefings, discussions, consultations, hearings,
and deliberations.

Given the intervals between PACHA meetings of 4 months, and the limited number of days we have available, we hope to repeat the conference-call briefings in which your participation was very much appreciated. The word-of-mouth about how useful this format was to the Research Committee members has resulted in requests from the entire Council (n=30, increasing to 35 soon) to be invited in the future to listen in, too.

Thank you and best regards.

Bruce

From: bolog003
To: bgw2; WEPaul
Subject: Re[2]: PACHA vaccine recommendations
Date: 21 June, 1996 12:24

Return-Path: <bolog003@mc.duke.edu>
Received: from cdc1 by SmtpIn.em.cdc.gov id <31CA6A51@SmtpIn.em.cdc.gov>; Fri,
21 Jun 96 13:24:33 EST
Received: from DUKEMC.MC.DUKE.EDU by cdc1 (5.0/SMI-SVR4) id AA19105; Fri, 21 Jun 1996 13:26:47 -0400
Received: from ccmail.duke.edu by mc.duke.edu (PMDF V5.0-5 #11367) id <011665XQ3FZ4000P83@mc.duke.edu>; Fri, 21 Jun 1996 13:27:03 -0400 (EDT)
Date: Fri, 21 Jun 1996 12:24 -0400 (EDT)
From: bolog003@mc.duke.edu
Subject: Re[2]: PACHA vaccine recommendations
To: WEPaul@helix.nih.gov, bgw2@NIP1.EM.CDC.GOV
Message-Id: <011667FG0E20000P83@mc.duke.edu>
Mime-Version: 1.0
Content-Type: MULTIPART/MIXED; BOUNDARY="Boundary (ID q1x6897/navluxUXufbDQg)"
content-length: 5380

--

--Boundary (ID q1x6897/navluxUXufbDQg)
Content-type: TEXT/PLAIN

Bruce, the OAR Report (that you probably still have not yet seen in toto) urges the NIH to take the LEAD in driving research necessary for developmment of a vaccine. The language can be made stronger here, in my opinion. As written, the importance of the public-pprivate partnership overshadows the vital role of NIH as the fulcrum for academia and industry.

Reply Separator

Subject: RE: PACHA vaccine recommendations (A-I)
Author: bgw2@NIP1.EM.CDC.GOV at Internet
Date: 6/21/96 11:46 AM

Dear Colleagues (A-I),

FYI, the Presidential Advisory Council on HIV and AIDS approved last week the revised wording for the Research Committee's recommendation no. 4, following the complaint from the OAR that the NIH role had been ignored in the original version promulgated on April 26, 1996.

Below is the final official wording. I think it's actually better than the original, even if the request for Federal funding of non-governmental efforts is implied rather than specific, as we plan to return to this issue at a later date.

"4. All agencies of the U.S. Government with experience in various phases of vaccine research and development -- including NIH with its lead role in basic research, DoD, FDA, CDC, and the VA -- have valuable roles to play and should contribute their unique institutional expertise, capabilities, resources, and collaborative relationships in a coordinated and expedited Federal effort towards the common goal to produce an effective preventive vaccine for AIDS. In addition -- recognizing the need for public-private partnerships and the involvement of other nations in a global effort, and the relative advantage of private-sector, non-profit organizations in rapidly filling gaps in targeted vaccine research, product development, and testing -- the concept of an independent international AIDS vaccine initiative should be strongly encouraged and developed."

I don't have yet the final paper version, including all the fancy fonts and word processing styles and format, or an electronic version of the

entire document with the recommendations from all the committees. If you need this soon, you will have to contact the Office of National AIDS Policy (Patsy Fleming, Jeff Levi, Jane Sanville) to get a copy. Their contact info

is: e-mail: LEVI_J@a1.eop.gov, Tel: 202-632-1090, Fax: 202-632-1096.

Best regards,
Bruce

--Boundary (ID q1x6897/navluxUXufbDQg)
Content-type: TEXT/PLAIN

RFC-822-headers:
Received: from cdc1 (cdc1.cdc.gov) by mc.duke.edu (PMDF V5.0-5 #11367)

id <01I66251TJRK001BWZ@mc.duke.edu> for bolog003@mc.duke.edu; Fri,
21 Jun 1996 10:55:07 -0400 (EDT)
Received: from SmtpOut.em.cdc.gov by cdc1 (5.0/SMI-SVR4) id AA10221; Fri,
21 Jun 1996 10:40:10 -0400
Received: by SmtpOut.em.cdc.gov with Microsoft Mail id
<31CA4344@SmtpOut.em.cdc.gov>; Fri, 21 Jun 1996 10:37:56 -0500 (EST)
Date: Fri, 21 Jun 1996 10:46:00 -0500 (EST)
From: "Weniger, Bruce" <bgw2@NIP1.EM.CDC.GOV>
Subject: RE: PACHA vaccine recommendations
To: "'Brown, Art (WRAIR/HJF)'" <abrown@hiv.hjf.org>,
"'Agosti, Jan (Immunex)'" <agosti@immunex.com>,
"Duliege, Anne-Marie (Chiron)" <anne-marie_duliege@cc.chiron.com>,
"Antunes, Carlos (UFMG Br)" <antunesc@vm1.lcc.ufmg.br>,
"'Gellin, Bruce (NIAID)'" <BGELLIN@mercury.niaid.nih.gov>,
"Bloom, Barry (AECoM, NY)" <bloom@aecom.yu.edu>
To: "Bolognesi, Dani (Duke)" <bolog003@mc.duke.edu>,
"Cohen, Jon (Science)" <cohenj@ix.netcom.com>,
"Collins, Chris (MAA)" <collins@maaids.ucsf.edu>,
"Curran, James (Emory SPH)" <curran@sph.emory.edu>,
"Henderson, CW (Weeklies)" <cwhender@hendersonnet.atl.ga.us>,
"'Burke, Don (WRAIR/HJF)'" <dburke@hiv.hjf.org>,
"Celentano, David (JHU)" <dcelenta@phnet.sph.jhu.edu>
To: "Doberstyn, Brian (personal)" <doberstn@health.moph.go.th>,
"'Francis, Don (Genenvax)'" <donaldf@emerald.gene.com>,
"Esparza, Jose (UNAIDS)" <esparzaj@who.ch>,
"Galvao-Castro, Bernardo (UFBA)" <fiocruz@ufba.br>,
"Halstead, Scott (USN)" <halsteads@mail-gw.nmrdc.nnmc.navy.mil>,
"Heyward, William (UNAIDS)" <heywardw@who.ch>
To: "'Hilleman, Maurice (Merck)'" <konarske@merck.com>,
"Clements, Mary Lou (JHU)" <mclement@phnet.sph.jhu.edu>,
"'Hankins, Catherine (Montreal)'" <MD77@MUSICA.MCGILL.CA>,
"Essex, Max (Harvard SPH)" <messex@hsph.harvard.edu>,
"Gold, Marthe R" <MGOLD@OSOPHS.SSW.DHHS.GOV>,
"Chequer, Pedro (MS Br)" <pchequer@gaia.fns.ms.gov.br>,
"Fast, Pat (NIH)" <PF13I@NIH.SSW.DHHS.GOV>
To: "Hoff, Rod (NIH)" <RH25V@NIH.SSW.DHHS.GOV>,
"'Dorman, Burt (Acrogen)'" <sammy@mendel.Berkeley.EDU>,
"Berkley, Seth (Rock.Fdn.)" <sberkley@rockfound.org>,
"Bowden, Sandra (FHI)" <sbowden@fhi.org>,
Chantapong c/o Ruengpung <sirst@mucc.mahidol.ac.th>,
"Bhamarapravati, Natth" <stnbm@mucc.mahidol.ac.th>,
"Cates, Ward (HIVNET/FHI)" <wcates@fhi.org>
Cc: "Betsy Biemann, M.P.W." <103423.355@CompuServe.COM>,
Denise Gray-Felder <dgray-felder@rockfound.org>,
Stefani Janicki <sjanicki@rockfound.org>
Message-id: <31CA4344@SmtpOut.em.cdc.gov>
X-Mailer: Microsoft Mail V3.0
Content-transfer-encoding: 7BIT
Encoding: 41 TEXT

--Boundary (ID q1x6897/navluxUXufbDQg)--
========== END ATTACHMENT 1 ==========

========== ATTACHMENT 2 ==========

ATT CREATION TIME/DATE:21-JUN-1996 14:11:00.00

ATT BODYPART TYPE:D

TEXT:
RFC-822-headers:
Received: from storm.eop.gov (storm.eop.gov)
 by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I668W0Q528001NJ3@PMDF.EOP.GOV> for
 LEVI_J@a1.eop.gov; Fri, 21 Jun 1996 14:08:38 -0400 (EDT)
Received: from cdc2 (cdc2.cdc.gov) by STORM.EOP.GOV (PMDF V5.0-7 #6879)
 id <01I668Z95Q2600007Z@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Fri,
 21 Jun 1996 14:11:16 -0700 (MST)
Received: from SmtpOut.em.cdc.gov by cdc2 (5.0/SMI-SVR4) id AA05272; Fri,
 21 Jun 1996 14:22:25 +0500
Received: by SmtpOut.em.cdc.gov with Microsoft Mail id
 <31CA74DF@SmtpOut.em.cdc.gov>; Fri, 21 Jun 1996 14:09:35 -0500 (EST)
========== END ATTACHMENT 2 ==========